{
    "id": 55,
    "premise": "none",
    "hypothesis": "Loss of PALB2 prevents the action of BRCA2 in joining undamaged repair molecules in HRR",
    "label": "entailment",
    "explanation": "Patient with a pathogenic mutation in PALB2.\nPALB2 encodes a binding partner that localises BRCA2 to sites of DNA damage and links BRCA1 and BRCA2 in HR repair and DNA damage.\nBRCA2 promotes the joining of undamaged homologous repair molecules via RAD51 homolog 1 in humans.",
    "results": {
        "semantic validity": false,
        "premise": null,
        "hypothesis": "Loss of PALB2 prevents the action of BRCA2 in joining undamaged repair molecules in HRR",
        "history explanation": [
            "0 iteration: Patient with a pathogenic mutation in PALB2.\nPALB2 encodes a binding partner that localises BRCA2 to sites of DNA damage and links BRCA1 and BRCA2 in HR repair and DNA damage.\nBRCA2 promotes the joining of undamaged homologous repair molecules via RAD51 homolog 1 in humans.",
            "1 iteration: Patient with a pathogenic mutation in PALB2.\nPALB2 encodes a binding partner that localises BRCA2 to sites of DNA damage and links BRCA1 and BRCA2 in HR repair and DNA damage.\nBRCA2 promotes the joining of undamaged homologous repair molecules via RAD51 homolog 1 in humans.",
            "2 iteration: Patient with a pathogenic mutation in PALBPALB2 encodes a binding partner that localises BRCA2 to sites of DNA damage and links BRCA1 and BRCA2 in HR repair and DNA damage.\nBRCA2 promotes the joining of undamaged homologous repair molecules via RAD51 homolog 1 in humans.\nLoss of PALB2 disrupts the localisation of BRCA2 to sites of DNA damage, preventing BRCA2 from promoting the joining of undamaged homologous repair molecules in HRR.",
            "3 iteration: Patient with a pathogenic mutation in PALBPALB2 encodes a binding partner that localises BRCA2 to sites of DNA damage and links BRCA1 and BRCA2 in HR repair and DNA damage.\nBRCA2 promotes the joining of undamaged homologous repair molecules via RAD51 homolog 1 in humans.\nLoss of PALB2 disrupts the localisation of BRCA2 to sites of DNA damage, preventing BRCA2 from promoting the joining of undamaged homologous repair molecules in HRR.",
            "4 iteration: Patient with a pathogenic mutation in PALBPALB2 encodes a binding partner that localises BRCA2 to sites of DNA damage and links BRCA1 and BRCA2 in HR repair and DNA damage.\nBRCA2 promotes the joining of undamaged homologous repair molecules via RAD51 homolog 1 in humans.\nLoss of PALB2 disrupts the localisation of BRCA2 to sites of DNA damage, which directly prevents BRCA2 from promoting the joining of undamaged homologous repair molecules in HRR.",
            "5 iteration: Patient with a pathogenic mutation in PALBPALB2 encodes a binding partner that localises BRCA2 to sites of DNA damage and links BRCA1 and BRCA2 in HR repair and DNA damage.\nBRCA2 promotes the joining of undamaged homologous repair molecules via RAD51 homolog 1 in humans.\nLoss of PALB2 disrupts the localisation of BRCA2 to sites of DNA damage, which directly prevents BRCA2 from promoting the joining of undamaged homologous repair molecules in HRR.",
            "6 iteration: A patient with a pathogenic mutation in PALB2 encodes a binding partner that localizes BRCA2 to sites of DNA damage and links BRCA1 and BRCA2 in HR repair and DNA damage.\nBRCA2 promotes the joining of undamaged homologous repair molecules via RAD51 homolog 1 in humans.\nLoss of PALB2 disrupts the localization of BRCA2 to sites of DNA damage, which directly prevents BRCA2 from promoting the joining of undamaged homologous repair molecules in HRR.\nThe disruption of BRCA2 localization due to the loss of PALB2 prevents BRCA2 from performing its role in HRR, specifically in joining undamaged repair molecules.",
            "7 iteration: A patient with a pathogenic mutation in PALB2 encodes a binding partner that localizes BRCA2 to sites of DNA damage and links BRCA1 and BRCA2 in HR repair and DNA damage.\nBRCA2 promotes the joining of undamaged homologous repair molecules via RAD51 homolog 1 in humans.\nLoss of PALB2 disrupts the localization of BRCA2 to sites of DNA damage, which directly prevents BRCA2 from promoting the joining of undamaged homologous repair molecules in HRR by disrupting its role in the repair process.\nThe disruption of BRCA2 localization due to the loss of PALB2 prevents BRCA2 from performing its role in HRR, specifically in joining undamaged repair molecules, because BRCA2 cannot access the repair sites.",
            "8 iteration: A patient with a pathogenic mutation in PALB2 encodes a binding partner that localizes BRCA2 to sites of DNA damage and links BRCA1 and BRCA2 in HR repair and DNA damage.\nBRCA2 promotes the joining of undamaged homologous repair molecules via RAD51 homolog 1 in humans.\nLoss of PALB2 disrupts the localization of BRCA2 to sites of DNA damage, which directly prevents BRCA2 from promoting the joining of undamaged homologous repair molecules in HRR by disrupting its role in the repair process.\nThe disruption of BRCA2 localization due to the loss of PALB2 prevents BRCA2 from performing its role in HRR, specifically in joining undamaged repair molecules, because BRCA2 cannot access the repair sites.",
            "9 iteration: A patient with a pathogenic mutation in PALB2 encodes a binding partner that localizes BRCA2 to sites of DNA damage and links BRCA1 and BRCA2 in HR repair and DNA damage.\nBRCA2 promotes the joining of undamaged homologous repair molecules via RAD51 homolog 1 in humans.\nLoss of PALB2 disrupts the localization of BRCA2 to sites of DNA damage, which directly prevents BRCA2 from promoting the joining of undamaged homologous repair molecules in HRR by disrupting its role in the repair process.\nThe disruption of BRCA2 localization due to the loss of PALB2 prevents BRCA2 from performing its role in HRR, specifically in joining undamaged repair molecules, because BRCA2 cannot access the repair sites.",
            "10 iteration: A patient with a pathogenic mutation in PALB2 encodes a binding partner that localizes BRCA2 to sites of DNA damage and links BRCA1 and BRCA2 in HR repair and DNA damage.\nBRCA2 promotes the joining of undamaged homologous repair molecules via RAD51 homolog 1 in humans.\nLoss of PALB2 disrupts the localization of BRCA2 to sites of DNA damage, which directly prevents BRCA2 from promoting the joining of undamaged homologous repair molecules in HRR by disrupting its role in the repair process.\nThe disruption of BRCA2 localization due to the loss of PALB2 prevents BRCA2 from performing its role in HRR, specifically in joining undamaged repair molecules, because BRCA2 cannot access the repair sites."
        ],
        "history semantic validity": [
            "0 iteration: False",
            "1 iteration: False",
            "2 iteration: False",
            "3 iteration: False",
            "4 iteration: False",
            "5 iteration: False",
            "6 iteration: False",
            "7 iteration: False",
            "8 iteration: False",
            "9 iteration: False",
            "10 iteration: False"
        ],
        "history critique output": [
            "0 iteration: {'syntactic validity': False, 'error code': '', 'solving time': 9.624048471450806, 'proof tactics': ['Type unification failed: Clash of types \"event\" and \"entity\"\\n\\nType error in application: incompatible operand type\\n\\nOperator:  PatientEvent e2 :: entity \\\\<Rightarrow> bool\\nOperand:   e1 :: event\\n', 'No proof state', 'Bad context for command \"oops\"\\\\<^here> -- using reset state'], 'code': 'theory clinical_55_0\\nimports Main\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  Patient :: \"entity \u21d2 bool\"\\n  Mutation :: \"entity \u21d2 bool\"\\n  Pathogenic :: \"entity \u21d2 bool\"\\n  PALB2 :: \"entity \u21d2 bool\"\\n  With :: \"entity \u21d2 entity \u21d2 bool\"\\n  In :: \"entity \u21d2 entity \u21d2 bool\"\\n  BindingPartner :: \"entity \u21d2 bool\"\\n  Encodes :: \"event \u21d2 bool\"\\n  Agent :: \"event \u21d2 entity \u21d2 bool\"\\n  PatientEvent :: \"event \u21d2 entity \u21d2 bool\"  (* Renamed to avoid conflict with Patient *)\\n  Localises :: \"event \u21d2 bool\"\\n  BRCA2 :: \"entity \u21d2 bool\"\\n  Sites :: \"entity \u21d2 bool\"\\n  DNADamage :: \"entity \u21d2 bool\"\\n  To :: \"entity \u21d2 entity \u21d2 bool\"\\n  Links :: \"event \u21d2 bool\"\\n  BRCA1 :: \"entity \u21d2 bool\"\\n  HRRepair :: \"entity \u21d2 bool\"\\n  Joining :: \"event \u21d2 bool\"\\n  Molecules :: \"entity \u21d2 bool\"\\n  Undamaged :: \"entity \u21d2 bool\"\\n  Homologous :: \"entity \u21d2 bool\"\\n  Repair :: \"entity \u21d2 bool\"\\n  Promotes :: \"event \u21d2 bool\"\\n  RAD51 :: \"entity \u21d2 bool\"\\n  Homolog1 :: \"entity \u21d2 bool\"\\n  Via :: \"entity \u21d2 entity \u21d2 bool\"\\n  Humans :: \"entity \u21d2 bool\"\\n  Loss :: \"entity \u21d2 bool\"\\n  Action :: \"entity \u21d2 bool\"\\n  Prevents :: \"event \u21d2 bool\"\\n  InHRR :: \"entity \u21d2 bool\"\\n\\n(* Explanation 1: Patient with a pathogenic mutation in PALB2. *)\\naxiomatization where\\n  explanation_1: \"\u2203x y z. Patient x \u2227 Mutation y \u2227 Pathogenic y \u2227 PALB2 z \u2227 With x y \u2227 In y z\"\\n\\n(* Explanation 2: PALB2 encodes a binding partner that localises BRCA2 to sites of DNA damage and links BRCA1 and BRCA2 in HR repair and DNA damage. *)\\naxiomatization where\\n  explanation_2: \"\u2203x y z w e1 e2 e3. PALB2 x \u2227 BindingPartner y \u2227 Encodes e1 \u2227 Agent e1 x \u2227 PatientEvent e1 y \u2227 Localises e2 \u2227 Agent e2 y \u2227 BRCA2 z \u2227 PatientEvent e2 z \u2227 Sites w \u2227 DNADamage w \u2227 To z w \u2227 Links e3 \u2227 Agent e3 y \u2227 BRCA1 z \u2227 BRCA2 z \u2227 HRRepair z \u2227 DNADamage z \u2227 In z w\"\\n\\n(* Explanation 3: BRCA2 promotes the joining of undamaged homologous repair molecules via RAD51 homolog 1 in humans. *)\\naxiomatization where\\n  explanation_3: \"\u2203x y z w e1 e2. BRCA2 x \u2227 Joining e1 \u2227 Agent e1 x \u2227 Molecules y \u2227 Undamaged y \u2227 Homologous y \u2227 Repair y \u2227 Promotes e2 \u2227 Agent e2 x \u2227 PatientEvent e2 y \u2227 RAD51 z \u2227 Homolog1 z \u2227 Via y z \u2227 Humans w \u2227 In y w\"\\n\\ntheorem hypothesis:\\n  assumes asm: \"Loss x \u2227 PALB2 x\"\\n  (* Hypothesis: Loss of PALB2 prevents the action of BRCA2 in joining undamaged repair molecules in HRR. *)\\n  shows \"\u2203x y z e1 e2. Loss x \u2227 PALB2 x \u2227 Action y \u2227 BRCA2 y \u2227 Joining e1 \u2227 Agent e1 y \u2227 Molecules z \u2227 Undamaged z \u2227 Repair z \u2227 InHRR z \u2227 Prevents e2 \u2227 Agent e2 x \u2227 PatientEvent e2 e1\"\\nproof -\\n  (* From the premise, we have the known information about the loss of PALB2. *)\\n  from asm have \"Loss x \u2227 PALB2 x\" <ATP>\\n  (* Explanation 2 states that PALB2 encodes a binding partner that localises BRCA2 to sites of DNA damage and links BRCA1 and BRCA2 in HR repair and DNA damage. *)\\n  (* If PALB2 is lost, this encoding and linking cannot occur, preventing BRCA2 from promoting the joining of undamaged homologous repair molecules. *)\\n  (* Explanation 3 states that BRCA2 promotes the joining of undamaged homologous repair molecules via RAD51 homolog 1 in humans. *)\\n  (* The loss of PALB2 prevents this action of BRCA2. *)\\n  then have \"Prevents e2 \u2227 Agent e2 x \u2227 PatientEvent e2 e1\" <ATP>\\n  (* Therefore, the loss of PALB2 prevents the action of BRCA2 in joining undamaged repair molecules in HRR. *)\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: patient has a pathogenic mutation in PALB2 (from Explanatory Sentence 1)\\nB: PALB2 encodes a binding partner that localises BRCA2 to sites of DNA damage (from Explanatory Sentence 2)\\nC: PALB2 links BRCA1 and BRCA2 in HR repair and DNA damage (from Explanatory Sentence 2)\\nD: BRCA2 promotes the joining of undamaged homologous repair molecules via RAD51 homolog 1 in humans (from Explanatory Sentence 3)\\n\\nLogical Relations:\\nImplies(A, B)\\nImplies(patient has a pathogenic mutation in PALB2, PALB2 encodes a binding partner that localises BRCA2 to sites of DNA damage)\\n--------\\nImplies(B, C)\\nImplies(PALB2 encodes a binding partner that localises BRCA2 to sites of DNA damage, PALB2 links BRCA1 and BRCA2 in HR repair and DNA damage)\\n--------\\nImplies(C, D)\\nImplies(PALB2 links BRCA1 and BRCA2 in HR repair and DNA damage, BRCA2 promotes the joining of undamaged homologous repair molecules via RAD51 homolog 1 in humans)\\n--------\\n\\nDerived Implications:\\nImplies(Not(D), Not(A))\\nImplies(Not(BRCA2 promotes the joining of undamaged homologous repair molecules via RAD51 homolog 1 in humans), Not(patient has a pathogenic mutation in PALB2))\\n--------\\nImplies(B, D)\\nImplies(PALB2 encodes a binding partner that localises BRCA2 to sites of DNA damage, BRCA2 promotes the joining of undamaged homologous repair molecules via RAD51 homolog 1 in humans)\\n--------\\nImplies(Not(D), Not(B))\\nImplies(Not(BRCA2 promotes the joining of undamaged homologous repair molecules via RAD51 homolog 1 in humans), Not(PALB2 encodes a binding partner that localises BRCA2 to sites of DNA damage))\\n--------\\nImplies(A, C)\\nImplies(patient has a pathogenic mutation in PALB2, PALB2 links BRCA1 and BRCA2 in HR repair and DNA damage)\\n--------\\nImplies(A, D)\\nImplies(patient has a pathogenic mutation in PALB2, BRCA2 promotes the joining of undamaged homologous repair molecules via RAD51 homolog 1 in humans)\\n--------\\nImplies(Not(C), Not(A))\\nImplies(Not(PALB2 links BRCA1 and BRCA2 in HR repair and DNA damage), Not(patient has a pathogenic mutation in PALB2))\\n--------\\n'}",
            "1 iteration: {'syntactic validity': True, 'error code': '(* Explanation 3 states that BRCA2 promotes the joining of undamaged homologous repair molecules via RAD51 homolog 1 in humans. *)\\n(* However, the loss of PALB2 implies that this action is prevented. *)\\n(* Therefore, we can conclude that the loss of PALB2 prevents the action of BRCA2 in joining undamaged repair molecules in HRR. *)\\nthen have \"Prevents e1 e2\" sledgehammer', 'solving time': 105.00207448005676, 'proof tactics': [], 'code': 'theory clinical_55_1\\nimports Main\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  Patient :: \"entity \u21d2 bool\"\\n  Mutation :: \"entity \u21d2 bool\"\\n  Pathogenic :: \"entity \u21d2 bool\"\\n  PALB2 :: \"entity \u21d2 bool\"\\n  With :: \"entity \u21d2 entity \u21d2 bool\"\\n  Partner :: \"entity \u21d2 bool\"\\n  Binding :: \"entity \u21d2 bool\"\\n  Encodes :: \"event \u21d2 bool\"\\n  Agent :: \"event \u21d2 entity \u21d2 bool\"\\n  PatientEvent :: \"event \u21d2 entity \u21d2 bool\"  (* Renamed to avoid conflict with Patient *)\\n  BRCA2 :: \"entity \u21d2 bool\"\\n  Sites :: \"entity \u21d2 bool\"\\n  Damage :: \"entity \u21d2 bool\"\\n  DNA :: \"entity \u21d2 bool\"\\n  Localises :: \"event \u21d2 bool\"\\n  To :: \"entity \u21d2 entity \u21d2 bool\"\\n  BRCA1 :: \"entity \u21d2 bool\"\\n  HRRepair :: \"entity \u21d2 bool\"\\n  Links :: \"event \u21d2 bool\"\\n  In :: \"entity \u21d2 entity \u21d2 bool\"\\n  Molecules :: \"entity \u21d2 bool\"\\n  Undamaged :: \"entity \u21d2 bool\"\\n  Homologous :: \"entity \u21d2 bool\"\\n  Repair :: \"entity \u21d2 bool\"\\n  Joining :: \"event \u21d2 bool\"\\n  RAD51 :: \"entity \u21d2 bool\"\\n  Homolog1 :: \"entity \u21d2 bool\"\\n  Via :: \"event \u21d2 entity \u21d2 bool\"\\n  Humans :: \"entity \u21d2 bool\"\\n  Loss :: \"entity \u21d2 bool\"\\n  Action :: \"event \u21d2 bool\"\\n  Prevents :: \"event \u21d2 event \u21d2 bool\"\\n  HRR :: \"entity \u21d2 bool\"\\n\\n(* Explanation 1: Patient with a pathogenic mutation in PALB2 *)\\naxiomatization where\\n  explanation_1: \"\u2203x y. Patient x \u2227 Mutation y \u2227 Pathogenic y \u2227 PALB2 y \u2227 With x y\"\\n\\n(* Explanation 2: PALB2 encodes a binding partner that localises BRCA2 to sites of DNA damage and links BRCA1 and BRCA2 in HR repair and DNA damage *)\\naxiomatization where\\n  explanation_2: \"\u2203x y z w e1 e2 e3. PALB2 x \u2227 Partner y \u2227 Binding y \u2227 Encodes e1 \u2227 Agent e1 x \u2227 PatientEvent e1 y \u2227 BRCA2 z \u2227 Sites w \u2227 Damage w \u2227 DNA w \u2227 Localises e2 \u2227 Agent e2 y \u2227 PatientEvent e2 z \u2227 To z w \u2227 BRCA1 z \u2227 HRRepair w \u2227 Links e3 \u2227 Agent e3 y \u2227 PatientEvent e3 z \u2227 In z w\"\\n\\n(* Explanation 3: BRCA2 promotes the joining of undamaged homologous repair molecules via RAD51 homolog 1 in humans *)\\naxiomatization where\\n  explanation_3: \"\u2203x y z w e1 e2. BRCA2 x \u2227 Molecules y \u2227 Undamaged y \u2227 Homologous y \u2227 Repair y \u2227 Joining e1 \u2227 Agent e1 x \u2227 PatientEvent e1 y \u2227 RAD51 z \u2227 Homolog1 z \u2227 Via e1 z \u2227 Humans w \u2227 In z w\"\\n\\ntheorem hypothesis:\\n  assumes asm: \"Loss x \u2227 PALB2 x \u2227 Action e1 \u2227 BRCA2 y \u2227 Molecules z \u2227 Undamaged z \u2227 Repair z \u2227 HRR z \u2227 Joining e2 \u2227 Agent e2 y \u2227 PatientEvent e2 z\"\\n  (* Hypothesis: Loss of PALB2 prevents the action of BRCA2 in joining undamaged repair molecules in HRR *)\\n  shows \"\u2203x y z e1 e2. Loss x \u2227 PALB2 x \u2227 Action e1 \u2227 BRCA2 y \u2227 Molecules z \u2227 Undamaged z \u2227 Repair z \u2227 HRR z \u2227 Joining e2 \u2227 Agent e2 y \u2227 PatientEvent e2 z \u2227 Prevents e1 e2\"\\nproof -\\n  (* From the premise, we have known information about the loss of PALB2 and the action of BRCA2. *)\\n  from asm have \"Loss x \u2227 PALB2 x \u2227 Action e1 \u2227 BRCA2 y \u2227 Molecules z \u2227 Undamaged z \u2227 Repair z \u2227 HRR z \u2227 Joining e2 \u2227 Agent e2 y \u2227 PatientEvent e2 z\" <ATP>\\n  (* Explanation 3 states that BRCA2 promotes the joining of undamaged homologous repair molecules via RAD51 homolog 1 in humans. *)\\n  (* However, the loss of PALB2 implies that this action is prevented. *)\\n  (* Therefore, we can conclude that the loss of PALB2 prevents the action of BRCA2 in joining undamaged repair molecules in HRR. *)\\n  then have \"Prevents e1 e2\" <ATP>\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: patient has a pathogenic mutation in PALB2 (from Explanatory Sentence 1)\\nB: PALB2 encodes a binding partner that localises BRCA2 to sites of DNA damage (from Explanatory Sentence 2)\\nC: PALB2 links BRCA1 and BRCA2 in HR repair and DNA damage (from Explanatory Sentence 2)\\nD: BRCA2 promotes the joining of undamaged homologous repair molecules via RAD51 homolog 1 in humans (from Explanatory Sentence 3)\\n\\nLogical Relations:\\nImplies(A, B)\\nImplies(patient has a pathogenic mutation in PALB2, PALB2 encodes a binding partner that localises BRCA2 to sites of DNA damage)\\n--------\\nImplies(A, C)\\nImplies(patient has a pathogenic mutation in PALB2, PALB2 links BRCA1 and BRCA2 in HR repair and DNA damage)\\n--------\\nImplies(B, D)\\nImplies(PALB2 encodes a binding partner that localises BRCA2 to sites of DNA damage, BRCA2 promotes the joining of undamaged homologous repair molecules via RAD51 homolog 1 in humans)\\n--------\\n\\nDerived Implications:\\nImplies(A, D)\\nImplies(patient has a pathogenic mutation in PALB2, BRCA2 promotes the joining of undamaged homologous repair molecules via RAD51 homolog 1 in humans)\\n--------\\nImplies(Not(D), Not(A))\\nImplies(Not(BRCA2 promotes the joining of undamaged homologous repair molecules via RAD51 homolog 1 in humans), Not(patient has a pathogenic mutation in PALB2))\\n--------\\n'}",
            "2 iteration: {'syntactic validity': False, 'error code': '', 'solving time': 0, 'proof tactics': [], 'code': 'theory clinical_55_2\\nimports Main\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  Patient :: \"entity \u21d2 bool\"\\n  Mutation :: \"entity \u21d2 bool\"\\n  PALBPALB2 :: \"entity \u21d2 bool\"\\n  BindingPartner :: \"entity \u21d2 bool\"\\n  BRCA2 :: \"entity \u21d2 bool\"\\n  DNA_DamageSites :: \"entity \u21d2 bool\"\\n  HRRepair :: \"entity \u21d2 bool\"\\n  DNA_Damage :: \"entity \u21d2 bool\"\\n  Encodes :: \"event \u21d2 bool\"\\n  Localises :: \"event \u21d2 bool\"\\n  Links :: \"event \u21d2 bool\"\\n  Agent :: \"event \u21d2 entity \u21d2 bool\"\\n  PatientEvent :: \"event \u21d2 entity \u21d2 bool\"  (* Renamed to avoid clash *)\\n  To :: \"entity \u21d2 entity \u21d2 bool\"\\n  In :: \"event \u21d2 entity \u21d2 bool\"\\n  RepairMolecules :: \"entity \u21d2 bool\"\\n  RAD51 :: \"entity \u21d2 bool\"\\n  Humans :: \"entity \u21d2 bool\"\\n  Joining :: \"event \u21d2 bool\"\\n  Via :: \"event \u21d2 entity \u21d2 bool\"\\n  Promotes :: \"event \u21d2 bool\"\\n  LossPALB2 :: \"entity \u21d2 bool\"\\n  Localisation :: \"event \u21d2 bool\"\\n  HRR :: \"entity \u21d2 bool\"\\n  Disrupts :: \"event \u21d2 bool\"\\n  Prevents :: \"event \u21d2 event \u21d2 bool\"\\n  Action :: \"event \u21d2 bool\"\\n  Promoting :: \"event \u21d2 bool\"  (* Added to resolve the introduced fixed type variable error *)\\n\\n(* Explanation 1: Patient with a pathogenic mutation in PALBPALB2 encodes a binding partner that localises BRCA2 to sites of DNA damage and links BRCA1 and BRCA2 in HR repair and DNA damage. *)\\naxiomatization where\\n  explanation_1: \"\u2203x y z w v u t e1 e2 e3. Patient x \u2227 Mutation y \u2227 PALBPALB2 y \u2227 BindingPartner z \u2227 BRCA2 w \u2227 DNA_DamageSites v \u2227 HRRepair u \u2227 DNA_Damage t \u2227 Encodes e1 \u2227 Agent e1 x \u2227 PatientEvent e1 z \u2227 Localises e2 \u2227 Agent e2 z \u2227 PatientEvent e2 w \u2227 To w v \u2227 Links e3 \u2227 Agent e3 z \u2227 PatientEvent e3 w \u2227 In e3 u \u2227 In e3 t\"\\n\\n(* Explanation 2: BRCA2 promotes the joining of undamaged homologous repair molecules via RAD51 homolog 1 in humans. *)\\naxiomatization where\\n  explanation_2: \"\u2203x y z w e1 e2. BRCA2 x \u2227 RepairMolecules y \u2227 RAD51 z \u2227 Humans w \u2227 Joining e1 \u2227 Agent e1 x \u2227 PatientEvent e1 y \u2227 Via e1 z \u2227 In e1 w \u2227 Promotes e2 \u2227 Agent e2 x \u2227 PatientEvent e2 y\"\\n\\n(* Explanation 3: Loss of PALB2 disrupts the localisation of BRCA2 to sites of DNA damage, preventing BRCA2 from promoting the joining of undamaged homologous repair molecules in HRR. *)\\naxiomatization where\\n  explanation_3: \"\u2200x y z w v e1 e2 e3 e4. LossPALB2 x \u2227 Localisation e1 \u2227 BRCA2 y \u2227 DNA_DamageSites z \u2227 RepairMolecules w \u2227 HRR v \u2227 Joining e2 \u2227 Agent e2 y \u2227 PatientEvent e2 w \u2227 In e2 v \u2227 Promoting e3 \u2227 Agent e3 y \u2227 PatientEvent e3 w \u2227 Disrupts e4 \u2227 Agent e4 x \u2227 PatientEvent e4 e1 \u2227 Prevents e4 e3\"\\n\\ntheorem hypothesis:\\n  assumes asm: \"LossPALB2 x \u2227 BRCA2 y \u2227 RepairMolecules z\"\\n  (* Hypothesis: Loss of PALB2 prevents the action of BRCA2 in joining undamaged repair molecules in HRR *)\\n  shows \"\u2200x y z e1 e2. LossPALB2 x \u2227 Action e1 \u2227 BRCA2 y \u2227 RepairMolecules z \u2227 Joining e2 \u2227 Agent e2 y \u2227 PatientEvent e2 z \u27f6 Prevents e1 e2\"\\nproof -\\n  (* From the premise, we have the known information about LossPALB2, BRCA2, and RepairMolecules. *)\\n  from asm have \"LossPALB2 x \u2227 BRCA2 y \u2227 RepairMolecules z\" <ATP>\\n  (* Explanation 3 provides the logical relation Implies(E, F), which states that loss of PALB2 disrupts the localisation of BRCA2 to sites of DNA damage, preventing BRCA2 from promoting the joining of undamaged homologous repair molecules in HRR. *)\\n  (* We can use this to infer that the loss of PALB2 prevents the action of BRCA2 in joining undamaged repair molecules in HRR. *)\\n  then have \"\u2200e1 e2. LossPALB2 x \u2227 Action e1 \u2227 Joining e2 \u2227 Agent e2 y \u2227 PatientEvent e2 z \u27f6 Prevents e1 e2\" <ATP>\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: patient has a pathogenic mutation in PALB2 (from Explanatory Sentence 1)\\nB: PALB2 encodes a binding partner that localises BRCA2 to sites of DNA damage (from Explanatory Sentence 1)\\nC: BRCA2 is localised to sites of DNA damage (from Explanatory Sentence 1)\\nD: BRCA2 promotes the joining of undamaged homologous repair molecules via RAD51 homolog 1 (from Explanatory Sentence 2)\\nE: loss of PALB2 disrupts the localisation of BRCA2 to sites of DNA damage (from Explanatory Sentence 3)\\nF: BRCA2 is prevented from promoting the joining of undamaged homologous repair molecules in HRR (from Explanatory Sentence 3)\\n\\nLogical Relations:\\nImplies(A, B)\\nImplies(patient has a pathogenic mutation in PALB2, PALB2 encodes a binding partner that localises BRCA2 to sites of DNA damage)\\n--------\\nImplies(B, C)\\nImplies(PALB2 encodes a binding partner that localises BRCA2 to sites of DNA damage, BRCA2 is localised to sites of DNA damage)\\n--------\\nImplies(C, D)\\nImplies(BRCA2 is localised to sites of DNA damage, BRCA2 promotes the joining of undamaged homologous repair molecules via RAD51 homolog 1)\\n--------\\nImplies(E, Not(C))\\nImplies(loss of PALB2 disrupts the localisation of BRCA2 to sites of DNA damage, Not(BRCA2 is localised to sites of DNA damage))\\n--------\\nImplies(E, F)\\nImplies(loss of PALB2 disrupts the localisation of BRCA2 to sites of DNA damage, BRCA2 is prevented from promoting the joining of undamaged homologous repair molecules in HRR)\\n--------\\n\\nDerived Implications:\\nImplies(E, Not(B))\\nImplies(loss of PALB2 disrupts the localisation of BRCA2 to sites of DNA damage, Not(PALB2 encodes a binding partner that localises BRCA2 to sites of DNA damage))\\n--------\\nImplies(Not(D), Not(A))\\nImplies(Not(BRCA2 promotes the joining of undamaged homologous repair molecules via RAD51 homolog 1), Not(patient has a pathogenic mutation in PALB2))\\n--------\\nImplies(B, Not(E))\\nImplies(PALB2 encodes a binding partner that localises BRCA2 to sites of DNA damage, Not(loss of PALB2 disrupts the localisation of BRCA2 to sites of DNA damage))\\n--------\\nImplies(B, D)\\nImplies(PALB2 encodes a binding partner that localises BRCA2 to sites of DNA damage, BRCA2 promotes the joining of undamaged homologous repair molecules via RAD51 homolog 1)\\n--------\\nImplies(Not(D), Not(B))\\nImplies(Not(BRCA2 promotes the joining of undamaged homologous repair molecules via RAD51 homolog 1), Not(PALB2 encodes a binding partner that localises BRCA2 to sites of DNA damage))\\n--------\\nImplies(A, C)\\nImplies(patient has a pathogenic mutation in PALB2, BRCA2 is localised to sites of DNA damage)\\n--------\\nImplies(A, D)\\nImplies(patient has a pathogenic mutation in PALB2, BRCA2 promotes the joining of undamaged homologous repair molecules via RAD51 homolog 1)\\n--------\\nImplies(A, Not(E))\\nImplies(patient has a pathogenic mutation in PALB2, Not(loss of PALB2 disrupts the localisation of BRCA2 to sites of DNA damage))\\n--------\\nImplies(Not(C), Not(A))\\nImplies(Not(BRCA2 is localised to sites of DNA damage), Not(patient has a pathogenic mutation in PALB2))\\n--------\\nImplies(E, Not(A))\\nImplies(loss of PALB2 disrupts the localisation of BRCA2 to sites of DNA damage, Not(patient has a pathogenic mutation in PALB2))\\n--------\\n'}",
            "3 iteration: {'syntactic validity': True, 'error code': '(* Explanation 3 provides a logical relation: Implies(E, F), which states that the loss of PALB2 disrupts the localisation of BRCA2, preventing BRCA2 from promoting the joining of undamaged homologous repair molecules in HRR. *)\\n(* Since we have Loss x and PALBPALB2 x, we can infer that BRCA2 is prevented from promoting the joining of undamaged homologous repair molecules in HRR. *)\\nthen have \"Prevents e2 \u2227 Agent e2 x \u2227 Promoting e1 \u2227 Agent e1 y \u2227 Joining e1 \u2227 Agent e1 z\" sledgehammer', 'solving time': 103.30227828025818, 'proof tactics': [], 'code': 'theory clinical_55_3\\nimports Main\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  Patient :: \"entity \u21d2 bool\"\\n  Mutation :: \"entity \u21d2 bool\"\\n  Pathogenic :: \"entity \u21d2 bool\"\\n  PALBPALB2 :: \"entity \u21d2 bool\"\\n  BindingPartner :: \"entity \u21d2 bool\"\\n  Encodes :: \"event \u21d2 bool\"\\n  Agent :: \"event \u21d2 entity \u21d2 bool\"\\n  Localises :: \"event \u21d2 bool\"\\n  BRCA2 :: \"entity \u21d2 bool\"\\n  SitesOfDamage :: \"entity \u21d2 bool\"\\n  Links :: \"event \u21d2 bool\"\\n  BRCA1 :: \"entity \u21d2 bool\"\\n  HRRepair :: \"event \u21d2 bool\"\\n  DNADamage :: \"event \u21d2 bool\"\\n  RepairMolecules :: \"entity \u21d2 bool\"\\n  Undamaged :: \"entity \u21d2 bool\"\\n  Homologous :: \"entity \u21d2 bool\"\\n  RAD51 :: \"entity \u21d2 bool\"\\n  Humans :: \"entity \u21d2 bool\"\\n  Joining :: \"event \u21d2 bool\"\\n  Promotes :: \"event \u21d2 bool\"\\n  Via :: \"event \u21d2 entity \u21d2 bool\"\\n  Loss :: \"entity \u21d2 bool\"\\n  Localisation :: \"event \u21d2 bool\"\\n  Disrupts :: \"event \u21d2 bool\"\\n  To :: \"event \u21d2 entity \u21d2 bool\"\\n  Prevents :: \"event \u21d2 bool\"\\n  Promoting :: \"event \u21d2 bool\"\\n  HRR :: \"entity \u21d2 bool\"\\n  Action :: \"event \u21d2 bool\"\\n\\n(* Explanation 1: Patient with a pathogenic mutation in PALBPALB2 encodes a binding partner that localises BRCA2 to sites of DNA damage and links BRCA1 and BRCA2 in HR repair and DNA damage. *)\\naxiomatization where\\n  explanation_1: \"\u2203x y z w u v e1 e2 e3. Patient x \u2227 Mutation y \u2227 Pathogenic y \u2227 PALBPALB2 y \u2227 BindingPartner z \u2227 Encodes e1 \u2227 Agent e1 x \u2227 Agent e1 z \u2227 Localises e2 \u2227 Agent e2 z \u2227 BRCA2 w \u2227 SitesOfDamage w \u2227 Links e3 \u2227 Agent e3 z \u2227 Agent e3 u \u2227 BRCA1 u \u2227 Agent e3 v \u2227 BRCA2 v \u2227 HRRepair e3 \u2227 DNADamage e3\"\\n\\n(* Explanation 2: BRCA2 promotes the joining of undamaged homologous repair molecules via RAD51 homolog 1 in humans. *)\\naxiomatization where\\n  explanation_2: \"\u2203x y z e1 e2. BRCA2 x \u2227 RepairMolecules y \u2227 Undamaged y \u2227 Homologous y \u2227 RAD51 z \u2227 Humans z \u2227 Joining e1 \u2227 Agent e1 x \u2227 Agent e1 y \u2227 Promotes e2 \u2227 Agent e2 x \u2227 Via e1 z\"\\n\\n(* Explanation 3: Loss of PALB2 disrupts the localisation of BRCA2 to sites of DNA damage, preventing BRCA2 from promoting the joining of undamaged homologous repair molecules in HRR. *)\\naxiomatization where\\n  explanation_3: \"\u2200x y z w e1 e2 e3 e4. Loss x \u2227 PALBPALB2 x \u2227 Localisation e1 \u2227 BRCA2 y \u2227 SitesOfDamage z \u2227 Disrupts e2 \u2227 Agent e2 x \u2227 To e1 z \u2227 Prevents e3 \u2227 Agent e3 x \u2227 Promoting e4 \u2227 Agent e4 y \u2227 Joining e4 \u2227 RepairMolecules w \u2227 Undamaged w \u2227 Homologous w \u2227 HRR w\"\\n\\ntheorem hypothesis:\\n  assumes asm: \"Loss x \u2227 PALBPALB2 x \u2227 BRCA2 y \u2227 RepairMolecules z \u2227 Undamaged z \u2227 HRR z\"\\n  (* Hypothesis: Loss of PALB2 prevents the action of BRCA2 in joining undamaged repair molecules in HRR *)\\n  shows \"\u2203x y z e1 e2. Loss x \u2227 PALBPALB2 x \u2227 Action e1 \u2227 BRCA2 y \u2227 RepairMolecules z \u2227 Undamaged z \u2227 HRR z \u2227 Prevents e2 \u2227 Agent e2 x \u2227 Joining e1 \u2227 Agent e1 y \u2227 Agent e1 z\"\\nproof -\\n  (* From the premise, we have the known information about the loss of PALB2, BRCA2, and repair molecules. *)\\n  from asm have \"Loss x \u2227 PALBPALB2 x \u2227 BRCA2 y \u2227 RepairMolecules z \u2227 Undamaged z \u2227 HRR z\" <ATP>\\n  (* Explanation 3 provides a logical relation: Implies(E, F), which states that the loss of PALB2 disrupts the localisation of BRCA2, preventing BRCA2 from promoting the joining of undamaged homologous repair molecules in HRR. *)\\n  (* Since we have Loss x and PALBPALB2 x, we can infer that BRCA2 is prevented from promoting the joining of undamaged homologous repair molecules in HRR. *)\\n  then have \"Prevents e2 \u2227 Agent e2 x \u2227 Promoting e1 \u2227 Agent e1 y \u2227 Joining e1 \u2227 Agent e1 z\" <ATP>\\n  (* We need to show that there exists an action e1 and prevention e2 that satisfy the hypothesis. *)\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: patient has a pathogenic mutation in PALB2 (from Explanatory Sentence 1)\\nB: PALB2 encodes a binding partner that localises BRCA2 to sites of DNA damage (from Explanatory Sentence 1)\\nC: BRCA2 links BRCA1 and BRCA2 in HR repair and DNA damage (from Explanatory Sentence 1)\\nD: BRCA2 promotes the joining of undamaged homologous repair molecules via RAD51 homolog 1 in humans (from Explanatory Sentence 2)\\nE: loss of PALB2 disrupts the localisation of BRCA2 to sites of DNA damage (from Explanatory Sentence 3)\\nF: BRCA2 is prevented from promoting the joining of undamaged homologous repair molecules in HRR (from Explanatory Sentence 3)\\n\\nLogical Relations:\\nImplies(A, B)\\nImplies(patient has a pathogenic mutation in PALB2, PALB2 encodes a binding partner that localises BRCA2 to sites of DNA damage)\\n--------\\nImplies(B, C)\\nImplies(PALB2 encodes a binding partner that localises BRCA2 to sites of DNA damage, BRCA2 links BRCA1 and BRCA2 in HR repair and DNA damage)\\n--------\\nImplies(C, D)\\nImplies(BRCA2 links BRCA1 and BRCA2 in HR repair and DNA damage, BRCA2 promotes the joining of undamaged homologous repair molecules via RAD51 homolog 1 in humans)\\n--------\\nImplies(E, F)\\nImplies(loss of PALB2 disrupts the localisation of BRCA2 to sites of DNA damage, BRCA2 is prevented from promoting the joining of undamaged homologous repair molecules in HRR)\\n--------\\nEquivalent(E, Not(B))\\nEquivalent(loss of PALB2 disrupts the localisation of BRCA2 to sites of DNA damage, Not(PALB2 encodes a binding partner that localises BRCA2 to sites of DNA damage))\\n--------\\nEquivalent(F, Not(D))\\nEquivalent(BRCA2 is prevented from promoting the joining of undamaged homologous repair molecules in HRR, Not(BRCA2 promotes the joining of undamaged homologous repair molecules via RAD51 homolog 1 in humans))\\n--------\\n\\nDerived Implications:\\nImplies(Not(C), Not(D))\\nImplies(Not(BRCA2 links BRCA1 and BRCA2 in HR repair and DNA damage), Not(BRCA2 promotes the joining of undamaged homologous repair molecules via RAD51 homolog 1 in humans))\\n--------\\nImplies(E, Not(D))\\nImplies(loss of PALB2 disrupts the localisation of BRCA2 to sites of DNA damage, Not(BRCA2 promotes the joining of undamaged homologous repair molecules via RAD51 homolog 1 in humans))\\n--------\\nImplies(D, B)\\nImplies(BRCA2 promotes the joining of undamaged homologous repair molecules via RAD51 homolog 1 in humans, PALB2 encodes a binding partner that localises BRCA2 to sites of DNA damage)\\n--------\\nImplies(Not(B), E)\\nImplies(Not(PALB2 encodes a binding partner that localises BRCA2 to sites of DNA damage), loss of PALB2 disrupts the localisation of BRCA2 to sites of DNA damage)\\n--------\\nImplies(Not(F), B)\\nImplies(Not(BRCA2 is prevented from promoting the joining of undamaged homologous repair molecules in HRR), PALB2 encodes a binding partner that localises BRCA2 to sites of DNA damage)\\n--------\\nImplies(Not(B), F)\\nImplies(Not(PALB2 encodes a binding partner that localises BRCA2 to sites of DNA damage), BRCA2 is prevented from promoting the joining of undamaged homologous repair molecules in HRR)\\n--------\\nImplies(D, C)\\nImplies(BRCA2 promotes the joining of undamaged homologous repair molecules via RAD51 homolog 1 in humans, BRCA2 links BRCA1 and BRCA2 in HR repair and DNA damage)\\n--------\\nImplies(E, Not(C))\\nImplies(loss of PALB2 disrupts the localisation of BRCA2 to sites of DNA damage, Not(BRCA2 links BRCA1 and BRCA2 in HR repair and DNA damage))\\n--------\\nImplies(F, E)\\nImplies(BRCA2 is prevented from promoting the joining of undamaged homologous repair molecules in HRR, loss of PALB2 disrupts the localisation of BRCA2 to sites of DNA damage)\\n--------\\nImplies(Not(F), C)\\nImplies(Not(BRCA2 is prevented from promoting the joining of undamaged homologous repair molecules in HRR), BRCA2 links BRCA1 and BRCA2 in HR repair and DNA damage)\\n--------\\nImplies(D, Not(F))\\nImplies(BRCA2 promotes the joining of undamaged homologous repair molecules via RAD51 homolog 1 in humans, Not(BRCA2 is prevented from promoting the joining of undamaged homologous repair molecules in HRR))\\n--------\\nImplies(Not(D), Not(A))\\nImplies(Not(BRCA2 promotes the joining of undamaged homologous repair molecules via RAD51 homolog 1 in humans), Not(patient has a pathogenic mutation in PALB2))\\n--------\\nImplies(C, Not(E))\\nImplies(BRCA2 links BRCA1 and BRCA2 in HR repair and DNA damage, Not(loss of PALB2 disrupts the localisation of BRCA2 to sites of DNA damage))\\n--------\\nImplies(Not(D), Not(B))\\nImplies(Not(BRCA2 promotes the joining of undamaged homologous repair molecules via RAD51 homolog 1 in humans), Not(PALB2 encodes a binding partner that localises BRCA2 to sites of DNA damage))\\n--------\\nImplies(Not(C), E)\\nImplies(Not(BRCA2 links BRCA1 and BRCA2 in HR repair and DNA damage), loss of PALB2 disrupts the localisation of BRCA2 to sites of DNA damage)\\n--------\\nImplies(Not(C), F)\\nImplies(Not(BRCA2 links BRCA1 and BRCA2 in HR repair and DNA damage), BRCA2 is prevented from promoting the joining of undamaged homologous repair molecules in HRR)\\n--------\\nImplies(Not(E), B)\\nImplies(Not(loss of PALB2 disrupts the localisation of BRCA2 to sites of DNA damage), PALB2 encodes a binding partner that localises BRCA2 to sites of DNA damage)\\n--------\\nImplies(B, Not(F))\\nImplies(PALB2 encodes a binding partner that localises BRCA2 to sites of DNA damage, Not(BRCA2 is prevented from promoting the joining of undamaged homologous repair molecules in HRR))\\n--------\\nImplies(F, Not(A))\\nImplies(BRCA2 is prevented from promoting the joining of undamaged homologous repair molecules in HRR, Not(patient has a pathogenic mutation in PALB2))\\n--------\\nImplies(Not(E), C)\\nImplies(Not(loss of PALB2 disrupts the localisation of BRCA2 to sites of DNA damage), BRCA2 links BRCA1 and BRCA2 in HR repair and DNA damage)\\n--------\\nImplies(F, Not(B))\\nImplies(BRCA2 is prevented from promoting the joining of undamaged homologous repair molecules in HRR, Not(PALB2 encodes a binding partner that localises BRCA2 to sites of DNA damage))\\n--------\\nImplies(A, C)\\nImplies(patient has a pathogenic mutation in PALB2, BRCA2 links BRCA1 and BRCA2 in HR repair and DNA damage)\\n--------\\nImplies(D, Not(E))\\nImplies(BRCA2 promotes the joining of undamaged homologous repair molecules via RAD51 homolog 1 in humans, Not(loss of PALB2 disrupts the localisation of BRCA2 to sites of DNA damage))\\n--------\\nImplies(Not(F), D)\\nImplies(Not(BRCA2 is prevented from promoting the joining of undamaged homologous repair molecules in HRR), BRCA2 promotes the joining of undamaged homologous repair molecules via RAD51 homolog 1 in humans)\\n--------\\nImplies(Not(E), Not(F))\\nImplies(Not(loss of PALB2 disrupts the localisation of BRCA2 to sites of DNA damage), Not(BRCA2 is prevented from promoting the joining of undamaged homologous repair molecules in HRR))\\n--------\\nImplies(A, Not(E))\\nImplies(patient has a pathogenic mutation in PALB2, Not(loss of PALB2 disrupts the localisation of BRCA2 to sites of DNA damage))\\n--------\\nImplies(A, Not(F))\\nImplies(patient has a pathogenic mutation in PALB2, Not(BRCA2 is prevented from promoting the joining of undamaged homologous repair molecules in HRR))\\n--------\\nImplies(Not(D), F)\\nImplies(Not(BRCA2 promotes the joining of undamaged homologous repair molecules via RAD51 homolog 1 in humans), BRCA2 is prevented from promoting the joining of undamaged homologous repair molecules in HRR)\\n--------\\nImplies(Not(C), Not(A))\\nImplies(Not(BRCA2 links BRCA1 and BRCA2 in HR repair and DNA damage), Not(patient has a pathogenic mutation in PALB2))\\n--------\\nImplies(E, Not(A))\\nImplies(loss of PALB2 disrupts the localisation of BRCA2 to sites of DNA damage, Not(patient has a pathogenic mutation in PALB2))\\n--------\\nImplies(Not(B), Not(D))\\nImplies(Not(PALB2 encodes a binding partner that localises BRCA2 to sites of DNA damage), Not(BRCA2 promotes the joining of undamaged homologous repair molecules via RAD51 homolog 1 in humans))\\n--------\\nImplies(Not(D), E)\\nImplies(Not(BRCA2 promotes the joining of undamaged homologous repair molecules via RAD51 homolog 1 in humans), loss of PALB2 disrupts the localisation of BRCA2 to sites of DNA damage)\\n--------\\nImplies(E, Not(B))\\nImplies(loss of PALB2 disrupts the localisation of BRCA2 to sites of DNA damage, Not(PALB2 encodes a binding partner that localises BRCA2 to sites of DNA damage))\\n--------\\nImplies(B, Not(E))\\nImplies(PALB2 encodes a binding partner that localises BRCA2 to sites of DNA damage, Not(loss of PALB2 disrupts the localisation of BRCA2 to sites of DNA damage))\\n--------\\nImplies(B, D)\\nImplies(PALB2 encodes a binding partner that localises BRCA2 to sites of DNA damage, BRCA2 promotes the joining of undamaged homologous repair molecules via RAD51 homolog 1 in humans)\\n--------\\nImplies(C, B)\\nImplies(BRCA2 links BRCA1 and BRCA2 in HR repair and DNA damage, PALB2 encodes a binding partner that localises BRCA2 to sites of DNA damage)\\n--------\\nImplies(F, Not(D))\\nImplies(BRCA2 is prevented from promoting the joining of undamaged homologous repair molecules in HRR, Not(BRCA2 promotes the joining of undamaged homologous repair molecules via RAD51 homolog 1 in humans))\\n--------\\nImplies(Not(B), Not(C))\\nImplies(Not(PALB2 encodes a binding partner that localises BRCA2 to sites of DNA damage), Not(BRCA2 links BRCA1 and BRCA2 in HR repair and DNA damage))\\n--------\\nImplies(Not(E), D)\\nImplies(Not(loss of PALB2 disrupts the localisation of BRCA2 to sites of DNA damage), BRCA2 promotes the joining of undamaged homologous repair molecules via RAD51 homolog 1 in humans)\\n--------\\nImplies(A, D)\\nImplies(patient has a pathogenic mutation in PALB2, BRCA2 promotes the joining of undamaged homologous repair molecules via RAD51 homolog 1 in humans)\\n--------\\nImplies(F, Not(C))\\nImplies(BRCA2 is prevented from promoting the joining of undamaged homologous repair molecules in HRR, Not(BRCA2 links BRCA1 and BRCA2 in HR repair and DNA damage))\\n--------\\nImplies(C, Not(F))\\nImplies(BRCA2 links BRCA1 and BRCA2 in HR repair and DNA damage, Not(BRCA2 is prevented from promoting the joining of undamaged homologous repair molecules in HRR))\\n--------\\n'}",
            "4 iteration: {'syntactic validity': False, 'error code': '', 'solving time': 12.15946888923645, 'proof tactics': ['Type unification failed: Clash of types \"_ \\\\<Rightarrow> _\" and \"bool\"\\n\\nType error in application: operator not of function type\\n\\nOperator:  Prevents e1 :: bool\\nOperand:   e2 :: event\\n', 'No proof state', 'Bad context for command \"oops\"\\\\<^here> -- using reset state'], 'code': 'theory clinical_55_4\\nimports Main\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  Patient :: \"entity \u21d2 bool\"\\n  Mutation :: \"entity \u21d2 bool\"\\n  PALBPALB2 :: \"entity \u21d2 bool\"\\n  BindingPartner :: \"entity \u21d2 bool\"\\n  Encodes :: \"event \u21d2 bool\"\\n  Localises :: \"event \u21d2 bool\"\\n  BRCA2 :: \"entity \u21d2 bool\"\\n  SitesDNA :: \"entity \u21d2 bool\"\\n  Links :: \"event \u21d2 bool\"\\n  BRCA1 :: \"entity \u21d2 bool\"\\n  HRRepair :: \"event \u21d2 bool\"\\n  DNADamage :: \"event \u21d2 bool\"\\n  RepairMolecules :: \"entity \u21d2 bool\"\\n  RAD51 :: \"entity \u21d2 bool\"\\n  Humans :: \"entity \u21d2 bool\"\\n  Joining :: \"event \u21d2 bool\"  (* Corrected type to match event *)\\n  Agent :: \"event \u21d2 entity \u21d2 bool\"\\n  PatientEvent :: \"event \u21d2 entity \u21d2 bool\"  (* Renamed to avoid conflict *)\\n  Via :: \"event \u21d2 entity \u21d2 bool\"\\n  In :: \"event \u21d2 entity \u21d2 bool\"\\n  Promotes :: \"entity \u21d2 event \u21d2 bool\"\\n  LossPALB2 :: \"entity \u21d2 bool\"\\n  Localisation :: \"event \u21d2 bool\"\\n  Disrupts :: \"event \u21d2 bool\"\\n  To :: \"event \u21d2 entity \u21d2 bool\"\\n  Prevents :: \"event \u21d2 bool\"\\n  Promoting :: \"event \u21d2 entity \u21d2 bool\"\\n  HRR :: \"event \u21d2 bool\"\\n  Action :: \"event \u21d2 bool\"\\n\\n(* Explanation 1: Patient with a pathogenic mutation in PALBPALB2 encodes a binding partner that localises BRCA2 to sites of DNA damage and links BRCA1 and BRCA2 in HR repair and DNA damage. *)\\naxiomatization where\\n  explanation_1: \"\u2203x y z w e1 e2 e3. Patient x \u2227 Mutation y \u2227 PALBPALB2 y \u2227 BindingPartner z \u2227 Encodes e1 \u2227 Agent e1 x \u2227 PatientEvent e1 z \u2227 Localises e2 \u2227 Agent e2 z \u2227 PatientEvent e2 w \u2227 BRCA2 w \u2227 SitesDNA w \u2227 Links e3 \u2227 Agent e3 z \u2227 PatientEvent e3 x \u2227 PatientEvent e3 w \u2227 HRRepair e3 \u2227 DNADamage e3\"\\n\\n(* Explanation 2: BRCA2 promotes the joining of undamaged homologous repair molecules via RAD51 homolog 1 in humans. *)\\naxiomatization where\\n  explanation_2: \"\u2203x y z e1 e2. BRCA2 x \u2227 RepairMolecules y \u2227 RAD51 z \u2227 Humans e1 \u2227 Joining e2 \u2227 Agent e2 x \u2227 PatientEvent e2 y \u2227 Via e2 z \u2227 In e2 e1 \u2227 Promotes e1 e2\"\\n\\n(* Explanation 3: Loss of PALB2 disrupts the localisation of BRCA2 to sites of DNA damage, which directly prevents BRCA2 from promoting the joining of undamaged homologous repair molecules in HRR. *)\\naxiomatization where\\n  explanation_3: \"\u2200x y z w e1 e2 e3. LossPALB2 x \u2227 Localisation e1 \u2227 BRCA2 y \u2227 SitesDNA z \u2227 Disrupts e2 \u2227 Agent e2 x \u2227 PatientEvent e2 y \u2227 To e1 z \u2227 Prevents e3 \u2227 Agent e3 x \u2227 Promoting e3 y \u2227 Joining e3 \u2227 RepairMolecules w \u2227 HRR e3\"\\n\\ntheorem hypothesis:\\n  assumes asm: \"LossPALB2 x \u2227 BRCA2 y \u2227 RepairMolecules z\"\\n  (* Hypothesis: Loss of PALB2 prevents the action of BRCA2 in joining undamaged repair molecules in HRR. *)\\n  shows \"\u2200x y z e1 e2. LossPALB2 x \u2227 Action e1 \u2227 BRCA2 y \u2227 RepairMolecules z \u2227 Joining e2 \u2227 Agent e2 y \u2227 PatientEvent e2 z \u27f6 Prevents e1 e2\"\\nproof -\\n  (* From the premise, we have the known information about LossPALB2, BRCA2, and RepairMolecules. *)\\n  from asm have \"LossPALB2 x \u2227 BRCA2 y \u2227 RepairMolecules z\" <ATP>\\n  (* Explanation 3 provides a logical relation: Implies(E, F), which states that loss of PALB2 disrupts the localisation of BRCA2 to sites of DNA damage, and this disruption prevents BRCA2 from promoting the joining of undamaged homologous repair molecules in HRR. *)\\n  (* Since we have LossPALB2 x, we can infer the disruption and prevention. *)\\n  then have \"Prevents e1 e2\" <ATP>\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: patient has a pathogenic mutation in PALB2 (from Explanatory Sentence 1)\\nB: PALB2 encodes a binding partner that localises BRCA2 to sites of DNA damage (from Explanatory Sentence 1)\\nC: PALB2 links BRCA1 and BRCA2 in HR repair and DNA damage (from Explanatory Sentence 1)\\nD: BRCA2 promotes the joining of undamaged homologous repair molecules via RAD51 homolog 1 in humans (from Explanatory Sentence 2)\\nE: loss of PALB2 disrupts the localisation of BRCA2 to sites of DNA damage (from Explanatory Sentence 3)\\nF: disruption of BRCA2 localisation prevents BRCA2 from promoting the joining of undamaged homologous repair molecules in HRR (from Explanatory Sentence 3)\\n\\nLogical Relations:\\nImplies(A, B)\\nImplies(patient has a pathogenic mutation in PALB2, PALB2 encodes a binding partner that localises BRCA2 to sites of DNA damage)\\n--------\\nImplies(A, C)\\nImplies(patient has a pathogenic mutation in PALB2, PALB2 links BRCA1 and BRCA2 in HR repair and DNA damage)\\n--------\\nImplies(B, D)\\nImplies(PALB2 encodes a binding partner that localises BRCA2 to sites of DNA damage, BRCA2 promotes the joining of undamaged homologous repair molecules via RAD51 homolog 1 in humans)\\n--------\\nImplies(E, Not(B))\\nImplies(loss of PALB2 disrupts the localisation of BRCA2 to sites of DNA damage, Not(PALB2 encodes a binding partner that localises BRCA2 to sites of DNA damage))\\n--------\\nImplies(E, F)\\nImplies(loss of PALB2 disrupts the localisation of BRCA2 to sites of DNA damage, disruption of BRCA2 localisation prevents BRCA2 from promoting the joining of undamaged homologous repair molecules in HRR)\\n--------\\n\\nDerived Implications:\\nImplies(A, D)\\nImplies(patient has a pathogenic mutation in PALB2, BRCA2 promotes the joining of undamaged homologous repair molecules via RAD51 homolog 1 in humans)\\n--------\\nImplies(Not(D), Not(A))\\nImplies(Not(BRCA2 promotes the joining of undamaged homologous repair molecules via RAD51 homolog 1 in humans), Not(patient has a pathogenic mutation in PALB2))\\n--------\\nImplies(A, Not(E))\\nImplies(patient has a pathogenic mutation in PALB2, Not(loss of PALB2 disrupts the localisation of BRCA2 to sites of DNA damage))\\n--------\\nImplies(E, Not(A))\\nImplies(loss of PALB2 disrupts the localisation of BRCA2 to sites of DNA damage, Not(patient has a pathogenic mutation in PALB2))\\n--------\\n'}",
            "5 iteration: {'syntactic validity': True, 'error code': '(* Explanation 3 provides a logical relation Implies(E, F), which states that the loss of PALB2 disrupts the localisation of BRCA2 to sites of DNA damage, and this disruption prevents BRCA2 from promoting the joining of undamaged homologous repair molecules in HRR. *)\\n(* Since we have Loss x \u2227 PALB2 x, we can infer the disruption and prevention as described in Explanation 3. *)\\nthen have \"Prevents e1 \u2227 Agent e1 y \u2227 Promoting e3 \u2227 Agent e3 y \u2227 Molecules z \u2227 Undamaged z \u2227 Homologous z \u2227 Repair z \u2227 HRR z \u2227 Joining e3 \u2227 Agent e3 z\" sledgehammer', 'solving time': 103.16364288330078, 'proof tactics': [], 'code': 'theory clinical_55_5\\nimports Main\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  Patient :: \"entity \u21d2 bool\"\\n  Mutation :: \"entity \u21d2 bool\"\\n  Pathogenic :: \"entity \u21d2 bool\"\\n  PALBPALB2 :: \"entity \u21d2 bool\"\\n  BindingPartner :: \"entity \u21d2 bool\"\\n  Encodes :: \"event \u21d2 bool\"\\n  Agent :: \"event \u21d2 entity \u21d2 bool\"\\n  Localises :: \"event \u21d2 bool\"\\n  BRCA2 :: \"entity \u21d2 bool\"\\n  Sites :: \"entity \u21d2 bool\"\\n  DNADamage :: \"entity \u21d2 bool\"\\n  To :: \"entity \u21d2 entity \u21d2 bool\"\\n  Links :: \"event \u21d2 bool\"\\n  BRCA1 :: \"entity \u21d2 bool\"\\n  HRRepair :: \"entity \u21d2 bool\"\\n  In :: \"entity \u21d2 entity \u21d2 bool\"\\n  Molecules :: \"entity \u21d2 bool\"\\n  Undamaged :: \"entity \u21d2 bool\"\\n  Homologous :: \"entity \u21d2 bool\"\\n  Repair :: \"entity \u21d2 bool\"\\n  RAD51 :: \"entity \u21d2 bool\"\\n  Homolog1 :: \"entity \u21d2 bool\"\\n  Humans :: \"entity \u21d2 bool\"\\n  Promotes :: \"event \u21d2 bool\"\\n  Joining :: \"event \u21d2 bool\"\\n  Via :: \"event \u21d2 entity \u21d2 bool\"\\n  Loss :: \"entity \u21d2 bool\"\\n  Localisation :: \"entity \u21d2 bool\"\\n  Disrupts :: \"event \u21d2 bool\"\\n  Prevents :: \"event \u21d2 bool\"\\n  Promoting :: \"event \u21d2 bool\"\\n  HRR :: \"entity \u21d2 bool\"\\n  Action :: \"entity \u21d2 bool\"\\n\\n(* Explanation 1: Patient with a pathogenic mutation in PALBPALB2 encodes a binding partner that localises BRCA2 to sites of DNA damage and links BRCA1 and BRCA2 in HR repair and DNA damage. *)\\naxiomatization where\\n  explanation_1: \"\u2203x y z w v u t e1 e2 e3. Patient x \u2227 Mutation y \u2227 Pathogenic y \u2227 PALBPALB2 y \u2227 BindingPartner z \u2227 Encodes e1 \u2227 Agent e1 x \u2227 Agent e1 z \u2227 Localises e2 \u2227 Agent e2 z \u2227 BRCA2 w \u2227 Sites v \u2227 DNADamage v \u2227 To w v \u2227 Links e3 \u2227 Agent e3 z \u2227 BRCA1 u \u2227 BRCA2 w \u2227 HRRepair t \u2227 DNADamage t \u2227 In u t \u2227 In w t\"\\n\\n(* Explanation 2: BRCA2 promotes the joining of undamaged homologous repair molecules via RAD51 homolog 1 in humans. *)\\naxiomatization where\\n  explanation_2: \"\u2203x y z w e1 e2. BRCA2 x \u2227 Molecules y \u2227 Undamaged y \u2227 Homologous y \u2227 Repair y \u2227 RAD51 z \u2227 Homolog1 z \u2227 Humans w \u2227 Promotes e1 \u2227 Agent e1 x \u2227 Joining e2 \u2227 Agent e2 x \u2227 Agent e2 y \u2227 Via e2 z \u2227 In x w\"\\n\\n(* Explanation 3: Loss of PALB2 disrupts the localisation of BRCA2 to sites of DNA damage, which directly prevents BRCA2 from promoting the joining of undamaged homologous repair molecules in HRR. *)\\naxiomatization where\\n  explanation_3: \"\u2203x y z w e1 e2 e3. Loss x \u2227 PALB2 x \u2227 Localisation y \u2227 BRCA2 y \u2227 Sites z \u2227 DNADamage z \u2227 Disrupts e1 \u2227 Agent e1 x \u2227 Agent e1 y \u2227 To y z \u2227 Prevents e2 \u2227 Agent e2 y \u2227 Promoting e3 \u2227 Agent e3 y \u2227 Molecules w \u2227 Undamaged w \u2227 Homologous w \u2227 Repair w \u2227 HRR w \u2227 Joining e3 \u2227 Agent e3 w\"\\n\\ntheorem hypothesis:\\n  assumes asm: \"Loss x \u2227 PALB2 x\"\\n  (* Hypothesis: Loss of PALB2 prevents the action of BRCA2 in joining undamaged repair molecules in HRR *)\\n  shows \"\u2203x y z e1 e2. Loss x \u2227 PALB2 x \u2227 Action y \u2227 BRCA2 y \u2227 Molecules z \u2227 Undamaged z \u2227 Repair z \u2227 HRR z \u2227 Prevents e1 \u2227 Agent e1 x \u2227 Agent e1 y \u2227 Joining e2 \u2227 Agent e2 y \u2227 Agent e2 z\"\\nproof -\\n  (* From the premise, we have the known information about the loss of PALB2. *)\\n  from asm have \"Loss x \u2227 PALB2 x\" <ATP>\\n  (* Explanation 3 provides a logical relation Implies(E, F), which states that the loss of PALB2 disrupts the localisation of BRCA2 to sites of DNA damage, and this disruption prevents BRCA2 from promoting the joining of undamaged homologous repair molecules in HRR. *)\\n  (* Since we have Loss x \u2227 PALB2 x, we can infer the disruption and prevention as described in Explanation 3. *)\\n  then have \"Prevents e1 \u2227 Agent e1 y \u2227 Promoting e3 \u2227 Agent e3 y \u2227 Molecules z \u2227 Undamaged z \u2227 Homologous z \u2227 Repair z \u2227 HRR z \u2227 Joining e3 \u2227 Agent e3 z\" <ATP>\\n  (* We need to show that this prevention is equivalent to the hypothesis statement. *)\\n  then have \"\u2203x y z e1 e2. Loss x \u2227 PALB2 x \u2227 Action y \u2227 BRCA2 y \u2227 Molecules z \u2227 Undamaged z \u2227 Repair z \u2227 HRR z \u2227 Prevents e1 \u2227 Agent e1 x \u2227 Agent e1 y \u2227 Joining e2 \u2227 Agent e2 y \u2227 Agent e2 z\" <ATP>\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: patient has a pathogenic mutation in PALB2 (from Explanatory Sentence 1)\\nB: PALB2 encodes a binding partner that localises BRCA2 to sites of DNA damage (from Explanatory Sentence 1)\\nC: PALB2 links BRCA1 and BRCA2 in HR repair and DNA damage (from Explanatory Sentence 1)\\nD: BRCA2 promotes the joining of undamaged homologous repair molecules via RAD51 homolog 1 in humans (from Explanatory Sentence 2)\\nE: loss of PALB2 disrupts the localisation of BRCA2 to sites of DNA damage (from Explanatory Sentence 3)\\nF: disruption of BRCA2 localisation prevents BRCA2 from promoting the joining of undamaged homologous repair molecules in HRR (from Explanatory Sentence 3)\\n\\nLogical Relations:\\nImplies(A, Not(B))\\nImplies(patient has a pathogenic mutation in PALB2, Not(PALB2 encodes a binding partner that localises BRCA2 to sites of DNA damage))\\n--------\\nImplies(Not(B), Not(D))\\nImplies(Not(PALB2 encodes a binding partner that localises BRCA2 to sites of DNA damage), Not(BRCA2 promotes the joining of undamaged homologous repair molecules via RAD51 homolog 1 in humans))\\n--------\\nImplies(E, F)\\nImplies(loss of PALB2 disrupts the localisation of BRCA2 to sites of DNA damage, disruption of BRCA2 localisation prevents BRCA2 from promoting the joining of undamaged homologous repair molecules in HRR)\\n--------\\n\\nDerived Implications:\\nImplies(A, Not(D))\\nImplies(patient has a pathogenic mutation in PALB2, Not(BRCA2 promotes the joining of undamaged homologous repair molecules via RAD51 homolog 1 in humans))\\n--------\\nImplies(D, Not(A))\\nImplies(BRCA2 promotes the joining of undamaged homologous repair molecules via RAD51 homolog 1 in humans, Not(patient has a pathogenic mutation in PALB2))\\n--------\\n'}",
            "6 iteration: {'syntactic validity': True, 'error code': '(* Explanation 3 states that the loss of PALB2 disrupts the localization of BRCA2, which prevents BRCA2 from promoting the joining of undamaged homologous repair molecules in HRR. *)\\n(* This aligns with the logical relation Implies(D, E), where D is the loss of PALB2 disrupting BRCA2 localization, and E is the prevention of BRCA2\\'s action in HRR. *)\\nthen have \"Prevents e1 \u2227 Agent e1 x \u2227 Agent e1 y \u2227 Joining e2 \u2227 Agent e2 y \u2227 Agent e2 z\" sledgehammer', 'solving time': 103.20588541030884, 'proof tactics': [], 'code': 'theory clinical_55_6\\nimports Main\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  Patient :: \"entity \u21d2 bool\"\\n  Mutation :: \"entity \u21d2 bool\"\\n  Pathogenic :: \"entity \u21d2 bool\"\\n  PALB2 :: \"entity \u21d2 bool\"\\n  BindingPartner :: \"entity \u21d2 bool\"\\n  Encodes :: \"event \u21d2 bool\"\\n  Agent :: \"event \u21d2 entity \u21d2 bool\"\\n  Localizes :: \"event \u21d2 bool\"\\n  BRCA2 :: \"entity \u21d2 bool\"\\n  Sites :: \"entity \u21d2 bool\"\\n  Damage :: \"entity \u21d2 bool\"\\n  DNA :: \"entity \u21d2 bool\"\\n  To :: \"entity \u21d2 entity \u21d2 bool\"\\n  Links :: \"event \u21d2 bool\"\\n  BRCA1 :: \"entity \u21d2 bool\"\\n  HRRepair :: \"entity \u21d2 bool\"\\n  Promotes :: \"event \u21d2 bool\"\\n  Molecules :: \"entity \u21d2 bool\"\\n  Undamaged :: \"entity \u21d2 bool\"\\n  Homologous :: \"entity \u21d2 bool\"\\n  Repair :: \"entity \u21d2 bool\"\\n  RAD51 :: \"entity \u21d2 bool\"\\n  Homolog1 :: \"entity \u21d2 bool\"\\n  Humans :: \"entity \u21d2 bool\"\\n  Joining :: \"event \u21d2 bool\"\\n  Via :: \"event \u21d2 entity \u21d2 bool\"\\n  In :: \"event \u21d2 entity \u21d2 bool\"\\n  Loss :: \"entity \u21d2 bool\"\\n  Localization :: \"entity \u21d2 bool\"\\n  Disrupts :: \"event \u21d2 bool\"\\n  Prevents :: \"event \u21d2 bool\"\\n  Promoting :: \"event \u21d2 bool\"\\n  HRR :: \"entity \u21d2 bool\"\\n  Disruption :: \"entity \u21d2 bool\"\\n  DueTo :: \"entity \u21d2 entity \u21d2 bool\"\\n  Performing :: \"event \u21d2 bool\"\\n  Role :: \"entity \u21d2 bool\"\\n  Action :: \"entity \u21d2 bool\"\\n\\n(* Explanation 1: A patient with a pathogenic mutation in PALB2 encodes a binding partner that localizes BRCA2 to sites of DNA damage and links BRCA1 and BRCA2 in HR repair and DNA damage. *)\\naxiomatization where\\n  explanation_1: \"\u2203x y z w v e1 e2 e3. Patient x \u2227 Mutation y \u2227 Pathogenic y \u2227 PALB2 y \u2227 BindingPartner z \u2227 Encodes e1 \u2227 Agent e1 x \u2227 Agent e1 z \u2227 Localizes e2 \u2227 Agent e2 z \u2227 BRCA2 w \u2227 Sites v \u2227 Damage v \u2227 DNA v \u2227 To w v \u2227 Links e3 \u2227 Agent e3 z \u2227 BRCA1 w \u2227 HRRepair v \u2227 Damage v \u2227 DNA v\"\\n\\n(* Explanation 2: BRCA2 promotes the joining of undamaged homologous repair molecules via RAD51 homolog 1 in humans. *)\\naxiomatization where\\n  explanation_2: \"\u2203x y z w e1 e2. BRCA2 x \u2227 Molecules y \u2227 Undamaged y \u2227 Homologous y \u2227 Repair y \u2227 RAD51 z \u2227 Homolog1 z \u2227 Humans w \u2227 Promotes e1 \u2227 Agent e1 x \u2227 Joining e2 \u2227 Agent e2 x \u2227 Agent e2 y \u2227 Via e2 z \u2227 In e2 w\"\\n\\n(* Explanation 3: Loss of PALB2 disrupts the localization of BRCA2 to sites of DNA damage, which directly prevents BRCA2 from promoting the joining of undamaged homologous repair molecules in HRR. *)\\naxiomatization where\\n  explanation_3: \"\u2200x y z w e1 e2 e3. Loss x \u2227 PALB2 x \u2227 Localization y \u2227 BRCA2 y \u2227 Sites z \u2227 Damage z \u2227 DNA z \u2227 Disrupts e1 \u2227 Agent e1 x \u2227 Agent e1 y \u2227 To y z \u2227 Prevents e2 \u2227 Agent e2 y \u2227 Promoting e3 \u2227 Agent e3 y \u2227 Joining e3 \u2227 Molecules w \u2227 Undamaged w \u2227 Homologous w \u2227 Repair w \u2227 HRR w\"\\n\\n(* Explanation 4: The disruption of BRCA2 localization due to the loss of PALB2 prevents BRCA2 from performing its role in HRR, specifically in joining undamaged repair molecules. *)\\naxiomatization where\\n  explanation_4: \"\u2200x y z w e1 e2. Disruption x \u2227 Localization y \u2227 BRCA2 y \u2227 Loss z \u2227 PALB2 z \u2227 DueTo x z \u2227 Prevents e1 \u2227 Agent e1 x \u2227 Agent e1 y \u2227 Performing e2 \u2227 Agent e2 y \u2227 Role y \u2227 HRR y \u2227 Joining e2 \u2227 Molecules w \u2227 Undamaged w \u2227 Repair w\"\\n\\ntheorem hypothesis:\\n  assumes asm: \"Loss x \u2227 PALB2 x \u2227 Action y \u2227 BRCA2 y \u2227 Molecules z \u2227 Undamaged z \u2227 Repair z \u2227 HRR z\"\\n  (* Hypothesis: Loss of PALB2 prevents the action of BRCA2 in joining undamaged repair molecules in HRR *)\\n  shows \"\u2203x y z e1 e2. Loss x \u2227 PALB2 x \u2227 Action y \u2227 BRCA2 y \u2227 Molecules z \u2227 Undamaged z \u2227 Repair z \u2227 HRR z \u2227 Prevents e1 \u2227 Agent e1 x \u2227 Agent e1 y \u2227 Joining e2 \u2227 Agent e2 y \u2227 Agent e2 z\"\\nproof -\\n  (* From the premise, we have the known information about the loss of PALB2 and its relation to BRCA2 and repair molecules. *)\\n  from asm have \"Loss x \u2227 PALB2 x \u2227 Action y \u2227 BRCA2 y \u2227 Molecules z \u2227 Undamaged z \u2227 Repair z \u2227 HRR z\" <ATP>\\n  (* Explanation 3 states that the loss of PALB2 disrupts the localization of BRCA2, which prevents BRCA2 from promoting the joining of undamaged homologous repair molecules in HRR. *)\\n  (* This aligns with the logical relation Implies(D, E), where D is the loss of PALB2 disrupting BRCA2 localization, and E is the prevention of BRCA2\\'s action in HRR. *)\\n  then have \"Prevents e1 \u2227 Agent e1 x \u2227 Agent e1 y \u2227 Joining e2 \u2227 Agent e2 y \u2227 Agent e2 z\" <ATP>\\n  (* Therefore, we can conclude the hypothesis that the loss of PALB2 prevents the action of BRCA2 in joining undamaged repair molecules in HRR. *)\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: patient has a pathogenic mutation in PALB2 (from Explanatory Sentence 1)\\nB: PALB2 encodes a binding partner that localizes BRCA2 to sites of DNA damage (from Explanatory Sentence 1)\\nC: BRCA2 promotes the joining of undamaged homologous repair molecules via RAD51 homolog 1 (from Explanatory Sentence 2)\\nD: Loss of PALB2 disrupts the localization of BRCA2 to sites of DNA damage (from Explanatory Sentence 3)\\nE: Disruption of BRCA2 localization prevents BRCA2 from promoting the joining of undamaged homologous repair molecules in HRR (from Explanatory Sentence 3 and 4)\\n\\nLogical Relations:\\nImplies(A, B)\\nImplies(patient has a pathogenic mutation in PALB2, PALB2 encodes a binding partner that localizes BRCA2 to sites of DNA damage)\\n--------\\nImplies(D, Not(B))\\nImplies(Loss of PALB2 disrupts the localization of BRCA2 to sites of DNA damage, Not(PALB2 encodes a binding partner that localizes BRCA2 to sites of DNA damage))\\n--------\\nImplies(Not(B), Not(C))\\nImplies(Not(PALB2 encodes a binding partner that localizes BRCA2 to sites of DNA damage), Not(BRCA2 promotes the joining of undamaged homologous repair molecules via RAD51 homolog 1))\\n--------\\nImplies(D, E)\\nImplies(Loss of PALB2 disrupts the localization of BRCA2 to sites of DNA damage, Disruption of BRCA2 localization prevents BRCA2 from promoting the joining of undamaged homologous repair molecules in HRR)\\n--------\\n\\nDerived Implications:\\nImplies(A, Not(D))\\nImplies(patient has a pathogenic mutation in PALB2, Not(Loss of PALB2 disrupts the localization of BRCA2 to sites of DNA damage))\\n--------\\nImplies(C, Not(D))\\nImplies(BRCA2 promotes the joining of undamaged homologous repair molecules via RAD51 homolog 1, Not(Loss of PALB2 disrupts the localization of BRCA2 to sites of DNA damage))\\n--------\\nImplies(D, Not(C))\\nImplies(Loss of PALB2 disrupts the localization of BRCA2 to sites of DNA damage, Not(BRCA2 promotes the joining of undamaged homologous repair molecules via RAD51 homolog 1))\\n--------\\nImplies(D, Not(A))\\nImplies(Loss of PALB2 disrupts the localization of BRCA2 to sites of DNA damage, Not(patient has a pathogenic mutation in PALB2))\\n--------\\n'}",
            "7 iteration: {'syntactic validity': False, 'error code': '', 'solving time': 10.453754425048828, 'proof tactics': ['Type unification failed: Clash of types \"_ \\\\<Rightarrow> _\" and \"bool\"\\n\\nType error in application: operator not of function type\\n\\nOperator:  Prevents e1 :: bool\\nOperand:   e2 :: event\\n', 'No proof state', 'Bad context for command \"oops\"\\\\<^here> -- using reset state'], 'code': 'theory clinical_55_7\\nimports Main\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\ntypedecl RepairSites  (* Added to define the type RepairSites *)\\n\\nconsts\\n  Patient :: \"entity \u21d2 bool\"  (* Corrected to only have one definition *)\\n  Mutation :: \"entity \u21d2 bool\"\\n  PALB2 :: \"entity \u21d2 bool\"\\n  BindingPartner :: \"entity \u21d2 bool\"\\n  BRCA2 :: \"entity \u21d2 bool\"\\n  DNA_DamageSites :: \"entity \u21d2 bool\"\\n  HRRepair :: \"entity \u21d2 bool\"\\n  DNA_Damage :: \"entity \u21d2 bool\"\\n  Encodes :: \"event \u21d2 bool\"\\n  Agent :: \"event \u21d2 entity \u21d2 bool\"\\n  Localizes :: \"event \u21d2 bool\"\\n  To :: \"entity \u21d2 entity \u21d2 bool\"\\n  Links :: \"event \u21d2 bool\"\\n  In :: \"event \u21d2 entity \u21d2 bool\"\\n  RepairMolecules :: \"entity \u21d2 bool\"\\n  RAD51 :: \"entity \u21d2 bool\"\\n  Humans :: \"entity \u21d2 bool\"\\n  Joining :: \"event \u21d2 bool\"\\n  Via :: \"event \u21d2 entity \u21d2 bool\"\\n  Promotes :: \"event \u21d2 bool\"\\n  LossOfPALB2 :: \"entity \u21d2 bool\"\\n  Localization :: \"event \u21d2 bool\"\\n  Disrupts :: \"event \u21d2 bool\"\\n  Prevents :: \"event \u21d2 bool\"\\n  Promoting :: \"event \u21d2 bool\"\\n  InHRR :: \"entity \u21d2 bool\"\\n  Role :: \"event \u21d2 entity \u21d2 bool\"\\n  Disruption :: \"event \u21d2 bool\"\\n  DueTo :: \"event \u21d2 entity \u21d2 bool\"\\n  Performing :: \"event \u21d2 bool\"\\n  Access :: \"event \u21d2 bool\"\\n  Action :: \"event \u21d2 bool\"\\n\\n(* Explanation 1: A patient with a pathogenic mutation in PALB2 encodes a binding partner that localizes BRCA2 to sites of DNA damage and links BRCA1 and BRCA2 in HR repair and DNA damage. *)\\naxiomatization where\\n  explanation_1: \"\u2203x y z w v u t e1 e2 e3. Patient x \u2227 Mutation y \u2227 PALB2 y \u2227 BindingPartner z \u2227 BRCA2 w \u2227 DNA_DamageSites v \u2227 HRRepair u \u2227 DNA_Damage t \u2227 Encodes e1 \u2227 Agent e1 x \u2227 Patient z \u2227 Localizes e2 \u2227 Agent e2 z \u2227 Patient w \u2227 To w v \u2227 Links e3 \u2227 Agent e3 z \u2227 Patient w \u2227 In e3 u \u2227 In e3 t\"\\n\\n(* Explanation 2: BRCA2 promotes the joining of undamaged homologous repair molecules via RAD51 homolog 1 in humans. *)\\naxiomatization where\\n  explanation_2: \"\u2203x y z w e1 e2. BRCA2 x \u2227 RepairMolecules y \u2227 RAD51 z \u2227 Humans w \u2227 Joining e1 \u2227 Agent e1 x \u2227 Patient y \u2227 Via e1 z \u2227 In e1 w \u2227 Promotes e2 \u2227 Agent e2 x \u2227 Patient y\"\\n\\n(* Explanation 3: Loss of PALB2 disrupts the localization of BRCA2 to sites of DNA damage, which directly prevents BRCA2 from promoting the joining of undamaged homologous repair molecules in HRR by disrupting its role in the repair process. *)\\naxiomatization where\\n  explanation_3: \"\u2203x y z w e1 e2 e3 e4 e5. LossOfPALB2 x \u2227 BRCA2 y \u2227 DNA_DamageSites z \u2227 RepairMolecules w \u2227 Localization e1 \u2227 Agent e1 y \u2227 To y z \u2227 Disrupts e2 \u2227 Agent e2 x \u2227 Patient y \u2227 Prevents e3 \u2227 Agent e3 x \u2227 Patient y \u2227 Promoting e4 \u2227 Agent e4 y \u2227 Patient w \u2227 InHRR w \u2227 Disrupts e5 \u2227 Agent e5 x \u2227 Role e5 y\"\\n\\n(* Explanation 4: The disruption of BRCA2 localization due to the loss of PALB2 prevents BRCA2 from performing its role in HRR, specifically in joining undamaged repair molecules, because BRCA2 cannot access the repair sites. *)\\naxiomatization where\\n  explanation_4: \"\u2203x y z w e1 e2 e3 e4 e5 e6. Disruption e1 \u2227 BRCA2 x \u2227 LossOfPALB2 y \u2227 RepairMolecules z \u2227 RepairSites w \u2227 Localization e2 \u2227 Agent e2 x \u2227 DueTo e2 y \u2227 Prevents e3 \u2227 Agent e3 x \u2227 Patient x \u2227 Performing e4 \u2227 Agent e4 x \u2227 Role e4 x \u2227 InHRR z \u2227 Joining e5 \u2227 Agent e5 x \u2227 Patient z \u2227 Access e6 \u2227 Agent e6 x \u2227 Patient w \u2227 \u00acAccess e6\"\\n\\ntheorem hypothesis:\\n  assumes asm: \"LossOfPALB2 x \u2227 BRCA2 y \u2227 RepairMolecules z \u2227 InHRR z\"\\n  (* Hypothesis: Loss of PALB2 prevents the action of BRCA2 in joining undamaged repair molecules in HRR *)\\n  shows \"\u2200x y z e1 e2. LossOfPALB2 x \u2227 Action e1 \u2227 BRCA2 y \u2227 RepairMolecules z \u2227 Joining e2 \u2227 Agent e2 y \u2227 Patient z \u2227 InHRR z \u27f6 Prevents e1 e2\"\\nproof -\\n  (* From the premise, we have the known information about LossOfPALB2, BRCA2, RepairMolecules, and InHRR. *)\\n  from asm have \"LossOfPALB2 x \u2227 BRCA2 y \u2227 RepairMolecules z \u2227 InHRR z\" <ATP>\\n  (* Explanation 3 provides the logical relation Implies(D, E), which states that the loss of PALB2 disrupts the localization of BRCA2, preventing it from promoting the joining of undamaged repair molecules in HRR. *)\\n  (* Since we have LossOfPALB2 x, we can infer the disruption of BRCA2 localization. *)\\n  then have \"Disruption of BRCA2 localization prevents BRCA2 from promoting the joining of undamaged homologous repair molecules in HRR\" <ATP>\\n  (* Explanation 4 provides the logical relation Implies(F, E), which states that if BRCA2 cannot access the repair sites, it prevents BRCA2 from promoting the joining of undamaged homologous repair molecules in HRR. *)\\n  (* Since the disruption prevents BRCA2 from accessing the repair sites, we can conclude the hypothesis. *)\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: patient has a pathogenic mutation in PALB2 (from Explanatory Sentence 1)\\nB: PALB2 encodes a binding partner that localizes BRCA2 to sites of DNA damage (from Explanatory Sentence 1)\\nC: BRCA2 promotes the joining of undamaged homologous repair molecules via RAD51 homolog 1 (from Explanatory Sentence 2)\\nD: Loss of PALB2 disrupts the localization of BRCA2 to sites of DNA damage (from Explanatory Sentence 3)\\nE: Disruption of BRCA2 localization prevents BRCA2 from promoting the joining of undamaged homologous repair molecules in HRR (from Explanatory Sentence 3)\\nF: BRCA2 cannot access the repair sites (from Explanatory Sentence 4)\\n\\nLogical Relations:\\nImplies(A, B)\\nImplies(patient has a pathogenic mutation in PALB2, PALB2 encodes a binding partner that localizes BRCA2 to sites of DNA damage)\\n--------\\nImplies(B, C)\\nImplies(PALB2 encodes a binding partner that localizes BRCA2 to sites of DNA damage, BRCA2 promotes the joining of undamaged homologous repair molecules via RAD51 homolog 1)\\n--------\\nImplies(D, E)\\nImplies(Loss of PALB2 disrupts the localization of BRCA2 to sites of DNA damage, Disruption of BRCA2 localization prevents BRCA2 from promoting the joining of undamaged homologous repair molecules in HRR)\\n--------\\nImplies(D, F)\\nImplies(Loss of PALB2 disrupts the localization of BRCA2 to sites of DNA damage, BRCA2 cannot access the repair sites)\\n--------\\nImplies(F, E)\\nImplies(BRCA2 cannot access the repair sites, Disruption of BRCA2 localization prevents BRCA2 from promoting the joining of undamaged homologous repair molecules in HRR)\\n--------\\n\\nDerived Implications:\\nImplies(A, C)\\nImplies(patient has a pathogenic mutation in PALB2, BRCA2 promotes the joining of undamaged homologous repair molecules via RAD51 homolog 1)\\n--------\\nImplies(Not(C), Not(A))\\nImplies(Not(BRCA2 promotes the joining of undamaged homologous repair molecules via RAD51 homolog 1), Not(patient has a pathogenic mutation in PALB2))\\n--------\\n'}",
            "8 iteration: {'syntactic validity': False, 'error code': '', 'solving time': 0, 'proof tactics': [], 'code': 'theory clinical_55_8\\nimports Main\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  Patient :: \"entity \u21d2 bool\"\\n  Mutation :: \"entity \u21d2 bool\"\\n  Pathogenic :: \"entity \u21d2 bool\"\\n  PALB2 :: \"entity \u21d2 bool\"\\n  BindingPartner :: \"entity \u21d2 bool\"\\n  Encodes :: \"event \u21d2 bool\"\\n  Agent :: \"event \u21d2 entity \u21d2 bool\"\\n  Localizes :: \"event \u21d2 bool\"\\n  SitesDNA :: \"event \u21d2 bool\"\\n  Links :: \"event \u21d2 bool\"\\n  BRCA2 :: \"entity \u21d2 bool\"\\n  BRCA1 :: \"entity \u21d2 bool\"\\n  InHRRepair :: \"event \u21d2 bool\"\\n  InDNADamage :: \"event \u21d2 bool\"\\n  Molecules :: \"entity \u21d2 bool\"\\n  Undamaged :: \"entity \u21d2 bool\"\\n  Homologous :: \"entity \u21d2 bool\"\\n  Repair :: \"entity \u21d2 bool\"\\n  RAD51 :: \"entity \u21d2 bool\"\\n  Joining :: \"event \u21d2 bool\"\\n  Via :: \"event \u21d2 entity \u21d2 bool\"\\n  InHumans :: \"event \u21d2 bool\"\\n  Promotes :: \"event \u21d2 event \u21d2 bool\"\\n  LossPALB2 :: \"entity \u21d2 bool\"\\n  Localization :: \"event \u21d2 bool\"\\n  Disrupts :: \"event \u21d2 bool\"\\n  To :: \"event \u21d2 entity \u21d2 bool\"\\n  Prevents :: \"event \u21d2 event \u21d2 bool\"\\n  Promoting :: \"event \u21d2 bool\"\\n  InHRR :: \"event \u21d2 bool\"\\n  DisruptsRole :: \"event \u21d2 bool\"\\n  Disruption :: \"event \u21d2 bool\"\\n  PerformingRole :: \"event \u21d2 bool\"\\n  Access :: \"event \u21d2 entity \u21d2 bool\"\\n  SitesRepair :: \"entity \u21d2 bool\"\\n  Action :: \"event \u21d2 bool\"\\n\\n(* Explanation 1: A patient with a pathogenic mutation in PALB2 encodes a binding partner that localizes BRCA2 to sites of DNA damage and links BRCA1 and BRCA2 in HR repair and DNA damage. *)\\naxiomatization where\\n  explanation_1: \"\u2203x y z w e1 e2 e3. Patient x \u2227 Mutation y \u2227 Pathogenic y \u2227 PALB2 z \u2227 BindingPartner w \u2227 Encodes e1 \u2227 Agent e1 x \u2227 Agent e1 w \u2227 Localizes e2 \u2227 Agent e2 w \u2227 Agent e2 y \u2227 SitesDNA e2 \u2227 Links e3 \u2227 Agent e3 w \u2227 Agent e3 x \u2227 Agent e3 y \u2227 InHRRepair e3 \u2227 InDNADamage e3\"\\n\\n(* Explanation 2: BRCA2 promotes the joining of undamaged homologous repair molecules via RAD51 homolog 1 in humans. *)\\naxiomatization where\\n  explanation_2: \"\u2203x y z e1 e2. BRCA2 x \u2227 Molecules y \u2227 Undamaged y \u2227 Homologous y \u2227 Repair y \u2227 RAD51 z \u2227 Joining e1 \u2227 Agent e1 x \u2227 Agent e1 y \u2227 Via e1 z \u2227 InHumans e1 \u2227 Promotes e2 e1\"\\n\\n(* Explanation 3: Loss of PALB2 disrupts the localization of BRCA2 to sites of DNA damage, which directly prevents BRCA2 from promoting the joining of undamaged homologous repair molecules in HRR by disrupting its role in the repair process. *)\\naxiomatization where\\n  explanation_3: \"\u2203x y z e1 e2 e3 e4. LossPALB2 x \u2227 Localization e1 \u2227 BRCA2 y \u2227 SitesDNA z \u2227 Disrupts e2 \u2227 Agent e2 x \u2227 Agent e2 y \u2227 To e1 y \u2227 Prevents e3 e4 \u2227 Promoting e4 \u2227 Agent e4 y \u2227 Joining e4 \u2227 Molecules z \u2227 Undamaged z \u2227 Homologous z \u2227 Repair z \u2227 InHRR e4 \u2227 DisruptsRole e4\"\\n\\n(* Explanation 4: The disruption of BRCA2 localization due to the loss of PALB2 prevents BRCA2 from performing its role in HRR, specifically in joining undamaged repair molecules, because BRCA2 cannot access the repair sites. *)\\naxiomatization where\\n  explanation_4: \"\u2203x y z e1 e2 e3. Disruption e1 \u2227 Localization e2 \u2227 BRCA2 x \u2227 LossPALB2 y \u2227 Prevents e3 e1 \u2227 Agent e3 x \u2227 PerformingRole e3 \u2227 InHRR e3 \u2227 Joining e3 \u2227 Molecules z \u2227 Undamaged z \u2227 Repair z \u2227 Access e3 z\"\\n\\ntheorem hypothesis:\\n  assumes asm: \"LossPALB2 x \u2227 Action e1 \u2227 BRCA2 y \u2227 Molecules z \u2227 Undamaged z \u2227 Repair z \u2227 Joining e2 \u2227 Agent e2 y \u2227 Agent e2 z \u2227 InHRR e2\"\\n  (* Hypothesis: Loss of PALB2 prevents the action of BRCA2 in joining undamaged repair molecules in HRR *)\\n  shows \"\u2200x y z e1 e2. LossPALB2 x \u2227 Action e1 \u2227 BRCA2 y \u2227 Molecules z \u2227 Undamaged z \u2227 Repair z \u2227 Joining e2 \u2227 Agent e2 y \u2227 Agent e2 z \u2227 InHRR e2 \u27f6 Prevents e1 e2\"\\nproof -\\n  (* From the premise, we have the known information about LossPALB2, Action, BRCA2, Molecules, Undamaged, Repair, Joining, Agent, and InHRR. *)\\n  from asm have \"LossPALB2 x \u2227 Action e1 \u2227 BRCA2 y \u2227 Molecules z \u2227 Undamaged z \u2227 Repair z \u2227 Joining e2 \u2227 Agent e2 y \u2227 Agent e2 z \u2227 InHRR e2\" <ATP>\\n  (* There is a logical relation Implies(D, E), which states that Loss of PALB2 disrupts the localization of BRCA2 to sites of DNA damage, and this disruption prevents BRCA2 from promoting the joining of undamaged homologous repair molecules in HRR. *)\\n  (* From explanation 3 and 4, we know that the disruption of BRCA2 localization due to the loss of PALB2 prevents BRCA2 from performing its role in HRR, specifically in joining undamaged repair molecules. *)\\n  (* Therefore, we can infer that the loss of PALB2 prevents the action of BRCA2 in joining undamaged repair molecules in HRR. *)\\n  then have \"Prevents e1 e2\" <ATP>\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: patient has a pathogenic mutation in PALB2 (from Explanatory Sentence 1)\\nB: PALB2 encodes a binding partner that localizes BRCA2 to sites of DNA damage (from Explanatory Sentence 1)\\nC: BRCA2 promotes the joining of undamaged homologous repair molecules via RAD51 homolog 1 in humans (from Explanatory Sentence 2)\\nD: Loss of PALB2 disrupts the localization of BRCA2 to sites of DNA damage (from Explanatory Sentence 3)\\nE: Disruption of BRCA2 localization prevents BRCA2 from promoting the joining of undamaged homologous repair molecules in HRR (from Explanatory Sentence 3 and 4)\\n\\nLogical Relations:\\nImplies(A, B)\\nImplies(patient has a pathogenic mutation in PALB2, PALB2 encodes a binding partner that localizes BRCA2 to sites of DNA damage)\\n--------\\nImplies(D, Not(C))\\nImplies(Loss of PALB2 disrupts the localization of BRCA2 to sites of DNA damage, Not(BRCA2 promotes the joining of undamaged homologous repair molecules via RAD51 homolog 1 in humans))\\n--------\\nImplies(D, E)\\nImplies(Loss of PALB2 disrupts the localization of BRCA2 to sites of DNA damage, Disruption of BRCA2 localization prevents BRCA2 from promoting the joining of undamaged homologous repair molecules in HRR)\\n--------\\n\\nDerived Implications:\\n'}",
            "9 iteration: {'syntactic validity': False, 'error code': '', 'solving time': 0, 'proof tactics': [], 'code': 'theory clinical_55_9\\nimports Main\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  Patient :: \"entity \u21d2 bool\"\\n  Mutation :: \"entity \u21d2 bool\"\\n  PALB2 :: \"entity \u21d2 bool\"\\n  BindingPartner :: \"entity \u21d2 bool\"\\n  BRCA2 :: \"entity \u21d2 bool\"\\n  DNA_DamageSites :: \"entity \u21d2 bool\"\\n  HRRepair :: \"entity \u21d2 bool\"\\n  DNA_Damage :: \"entity \u21d2 bool\"\\n  Encodes :: \"event \u21d2 bool\"\\n  Localizes :: \"event \u21d2 bool\"\\n  Links :: \"event \u21d2 bool\"\\n  To :: \"event \u21d2 entity \u21d2 bool\"\\n  In :: \"event \u21d2 entity \u21d2 bool\"\\n  Agent :: \"event \u21d2 entity \u21d2 bool\"\\n  PatientEvent :: \"event \u21d2 entity \u21d2 bool\"  (* Renamed to avoid conflict *)\\n  Promotes :: \"event \u21d2 bool\"\\n  UndamagedHomologousRepairMolecules :: \"entity \u21d2 bool\"\\n  RAD51Homolog1 :: \"entity \u21d2 bool\"\\n  Humans :: \"entity \u21d2 bool\"\\n  Joining :: \"event \u21d2 bool\"\\n  Via :: \"event \u21d2 entity \u21d2 bool\"\\n  LossPALB2 :: \"entity \u21d2 bool\"\\n  Disrupts :: \"event \u21d2 bool\"\\n  Prevents :: \"event \u21d2 bool\"\\n  Promoting :: \"event \u21d2 bool\"\\n  By :: \"event \u21d2 entity \u21d2 bool\"\\n  HRR :: \"entity \u21d2 bool\"\\n  RepairProcess :: \"entity \u21d2 bool\"\\n  Disruption :: \"event \u21d2 bool\"\\n  UndamagedRepairMolecules :: \"entity \u21d2 bool\"\\n  RepairSites :: \"entity \u21d2 bool\"\\n  DueTo :: \"event \u21d2 entity \u21d2 bool\"\\n  Performing :: \"event \u21d2 bool\"\\n  Because :: \"event \u21d2 event \u21d2 bool\"\\n  Access :: \"event \u21d2 bool\"\\n  Action :: \"event \u21d2 bool\"\\n\\n(* Explanation 1: A patient with a pathogenic mutation in PALB2 encodes a binding partner that localizes BRCA2 to sites of DNA damage and links BRCA1 and BRCA2 in HR repair and DNA damage. *)\\naxiomatization where\\n  explanation_1: \"\u2203x y z w v u t e1 e2 e3. Patient x \u2227 Mutation y \u2227 PALB2 y \u2227 BindingPartner z \u2227 BRCA2 w \u2227 DNA_DamageSites v \u2227 HRRepair u \u2227 DNA_Damage t \u2227 Encodes e1 \u2227 Agent e1 x \u2227 PatientEvent e1 z \u2227 Localizes e2 \u2227 Agent e2 z \u2227 PatientEvent e2 w \u2227 To e2 v \u2227 Links e3 \u2227 Agent e3 z \u2227 PatientEvent e3 w \u2227 In e3 u \u2227 In e3 t\"\\n\\n(* Explanation 2: BRCA2 promotes the joining of undamaged homologous repair molecules via RAD51 homolog 1 in humans. *)\\naxiomatization where\\n  explanation_2: \"\u2203x y z w e1 e2. BRCA2 x \u2227 UndamagedHomologousRepairMolecules y \u2227 RAD51Homolog1 z \u2227 Humans w \u2227 Joining e1 \u2227 Agent e1 x \u2227 PatientEvent e1 y \u2227 Via e1 z \u2227 In e1 w \u2227 Promotes e2 \u2227 Agent e2 x \u2227 PatientEvent e2 y\"\\n\\n(* Explanation 3: Loss of PALB2 disrupts the localization of BRCA2 to sites of DNA damage, which directly prevents BRCA2 from promoting the joining of undamaged homologous repair molecules in HRR by disrupting its role in the repair process. *)\\naxiomatization where\\n  explanation_3: \"\u2203x y z w v u e1 e2 e3 e4. LossPALB2 x \u2227 BRCA2 y \u2227 DNA_DamageSites z \u2227 UndamagedHomologousRepairMolecules w \u2227 HRR v \u2227 RepairProcess u \u2227 Localizes e1 \u2227 Agent e1 y \u2227 To e1 z \u2227 Disrupts e2 \u2227 Agent e2 x \u2227 PatientEvent e2 e1 \u2227 Prevents e3 \u2227 Agent e3 x \u2227 PatientEvent e3 y \u2227 Promoting e4 \u2227 Agent e4 y \u2227 PatientEvent e4 w \u2227 In e4 v \u2227 By e3 u\"\\n\\n(* Explanation 4: The disruption of BRCA2 localization due to the loss of PALB2 prevents BRCA2 from performing its role in HRR, specifically in joining undamaged repair molecules, because BRCA2 cannot access the repair sites. *)\\naxiomatization where\\n  explanation_4: \"\u2203x y z w v e1 e2 e3 e4 e5 e6. Disruption e1 \u2227 BRCA2 y \u2227 LossPALB2 x \u2227 HRR z \u2227 UndamagedRepairMolecules w \u2227 RepairSites v \u2227 Localizes e2 \u2227 Agent e2 y \u2227 DueTo e2 x \u2227 Prevents e3 \u2227 Agent e3 e1 \u2227 PatientEvent e3 y \u2227 Performing e4 \u2227 Agent e4 y \u2227 In e4 z \u2227 Joining e5 \u2227 Agent e5 y \u2227 PatientEvent e5 w \u2227 Because e3 (Access e6) \u2227 Agent e6 y \u2227 PatientEvent e6 v\"\\n\\ntheorem hypothesis:\\n  assumes asm: \"LossPALB2 x \u2227 BRCA2 y \u2227 UndamagedRepairMolecules z\"\\n  (* Hypothesis: Loss of PALB2 prevents the action of BRCA2 in joining undamaged repair molecules in HRR *)\\n  shows \"\u2200x y z e1 e2. LossPALB2 x \u2227 Action e1 \u2227 BRCA2 y \u2227 UndamagedRepairMolecules z \u2227 Joining e2 \u2227 Agent e2 y \u2227 PatientEvent e2 z \u2227 In e2 z \u27f6 Prevents e1 e2\"\\nproof -\\n  (* From the premise, we have known information about LossPALB2, BRCA2, and UndamagedRepairMolecules. *)\\n  from asm have \"LossPALB2 x \u2227 BRCA2 y \u2227 UndamagedRepairMolecules z\" <ATP>\\n  (* We have a logical relation Implies(D, E), which states that Loss of PALB2 disrupts the localization of BRCA2 to sites of DNA damage, and this disruption prevents BRCA2 from promoting the joining of undamaged homologous repair molecules in HRR. *)\\n  (* Since we have LossPALB2 x, we can infer the disruption of BRCA2 localization. *)\\n  then have \"Disruption of BRCA2 localization prevents BRCA2 from promoting the joining of undamaged homologous repair molecules in HRR\" <ATP>\\n  (* From this, we can conclude that the action of BRCA2 in joining undamaged repair molecules is prevented. *)\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: patient has a pathogenic mutation in PALB2 (from Explanatory Sentence 1)\\nB: PALB2 encodes a binding partner that localizes BRCA2 to sites of DNA damage (from Explanatory Sentence 1)\\nC: BRCA2 promotes the joining of undamaged homologous repair molecules via RAD51 homolog 1 (from Explanatory Sentence 2)\\nD: Loss of PALB2 disrupts the localization of BRCA2 to sites of DNA damage (from Explanatory Sentence 3)\\nE: Disruption of BRCA2 localization prevents BRCA2 from promoting the joining of undamaged homologous repair molecules in HRR (from Explanatory Sentence 3)\\nF: BRCA2 cannot access the repair sites (from Explanatory Sentence 4)\\n\\nLogical Relations:\\nImplies(A, B)\\nImplies(patient has a pathogenic mutation in PALB2, PALB2 encodes a binding partner that localizes BRCA2 to sites of DNA damage)\\n--------\\nImplies(D, Not(B))\\nImplies(Loss of PALB2 disrupts the localization of BRCA2 to sites of DNA damage, Not(PALB2 encodes a binding partner that localizes BRCA2 to sites of DNA damage))\\n--------\\nImplies(Not(B), Not(C))\\nImplies(Not(PALB2 encodes a binding partner that localizes BRCA2 to sites of DNA damage), Not(BRCA2 promotes the joining of undamaged homologous repair molecules via RAD51 homolog 1))\\n--------\\nImplies(D, E)\\nImplies(Loss of PALB2 disrupts the localization of BRCA2 to sites of DNA damage, Disruption of BRCA2 localization prevents BRCA2 from promoting the joining of undamaged homologous repair molecules in HRR)\\n--------\\nImplies(E, F)\\nImplies(Disruption of BRCA2 localization prevents BRCA2 from promoting the joining of undamaged homologous repair molecules in HRR, BRCA2 cannot access the repair sites)\\n--------\\n\\nDerived Implications:\\nImplies(C, Not(D))\\nImplies(BRCA2 promotes the joining of undamaged homologous repair molecules via RAD51 homolog 1, Not(Loss of PALB2 disrupts the localization of BRCA2 to sites of DNA damage))\\n--------\\nImplies(Not(F), Not(D))\\nImplies(Not(BRCA2 cannot access the repair sites), Not(Loss of PALB2 disrupts the localization of BRCA2 to sites of DNA damage))\\n--------\\nImplies(D, F)\\nImplies(Loss of PALB2 disrupts the localization of BRCA2 to sites of DNA damage, BRCA2 cannot access the repair sites)\\n--------\\nImplies(A, Not(D))\\nImplies(patient has a pathogenic mutation in PALB2, Not(Loss of PALB2 disrupts the localization of BRCA2 to sites of DNA damage))\\n--------\\nImplies(D, Not(C))\\nImplies(Loss of PALB2 disrupts the localization of BRCA2 to sites of DNA damage, Not(BRCA2 promotes the joining of undamaged homologous repair molecules via RAD51 homolog 1))\\n--------\\nImplies(D, Not(A))\\nImplies(Loss of PALB2 disrupts the localization of BRCA2 to sites of DNA damage, Not(patient has a pathogenic mutation in PALB2))\\n--------\\n'}",
            "10 iteration: {'syntactic validity': False, 'error code': '', 'solving time': 0, 'proof tactics': [], 'code': 'theory clinical_55_10\\nimports Main\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  Patient :: \"entity \u21d2 bool\"\\n  Mutation :: \"entity \u21d2 bool\"\\n  PALB2 :: \"entity \u21d2 bool\"\\n  BindingPartner :: \"entity \u21d2 bool\"\\n  Encodes :: \"event \u21d2 bool\"\\n  Agent :: \"event \u21d2 entity \u21d2 bool\"\\n  Localizes :: \"event \u21d2 bool\"\\n  BRCA2 :: \"entity \u21d2 bool\"\\n  SitesDNA :: \"entity \u21d2 bool\"\\n  Links :: \"event \u21d2 bool\"\\n  BRCA1 :: \"entity \u21d2 bool\"\\n  HRRepair :: \"event \u21d2 bool\"\\n  DNADamage :: \"event \u21d2 bool\"\\n  RepairMolecules :: \"entity \u21d2 bool\"\\n  RAD51 :: \"entity \u21d2 bool\"\\n  Joining :: \"event \u21d2 bool\"\\n  Via :: \"event \u21d2 entity \u21d2 bool\"\\n  Humans :: \"event \u21d2 bool\"\\n  Promotes :: \"event \u21d2 bool\"\\n  LossPALB2 :: \"entity \u21d2 bool\"\\n  Localization :: \"event \u21d2 bool\"\\n  Disrupts :: \"event \u21d2 bool\"\\n  To :: \"event \u21d2 entity \u21d2 bool\"\\n  Prevents :: \"event \u21d2 bool\"\\n  Promoting :: \"event \u21d2 bool\"\\n  InHRR :: \"event \u21d2 bool\"\\n  DisruptsRole :: \"event \u21d2 bool\"\\n  Disruption :: \"event \u21d2 bool\"\\n  PerformingRole :: \"event \u21d2 bool\"\\n  Access :: \"event \u21d2 entity \u21d2 bool\"\\n  RepairSites :: \"entity \u21d2 bool\"\\n  Action :: \"event \u21d2 bool\"\\n\\n(* Explanation 1: A patient with a pathogenic mutation in PALB2 encodes a binding partner that localizes BRCA2 to sites of DNA damage and links BRCA1 and BRCA2 in HR repair and DNA damage. *)\\naxiomatization where\\n  explanation_1: \"\u2203x y z w e1 e2 e3. Patient x \u2227 Mutation y \u2227 PALB2 y \u2227 BindingPartner z \u2227 Encodes e1 \u2227 Agent e1 x \u2227 Agent e1 z \u2227 Localizes e2 \u2227 Agent e2 z \u2227 Agent e2 w \u2227 BRCA2 w \u2227 SitesDNA w \u2227 Links e3 \u2227 Agent e3 z \u2227 Agent e3 w \u2227 BRCA1 w \u2227 HRRepair e3 \u2227 DNADamage e3\"\\n\\n(* Explanation 2: BRCA2 promotes the joining of undamaged homologous repair molecules via RAD51 homolog 1 in humans. *)\\naxiomatization where\\n  explanation_2: \"\u2203x y z e1 e2. BRCA2 x \u2227 RepairMolecules y \u2227 RAD51 z \u2227 Joining e1 \u2227 Agent e1 x \u2227 Agent e1 y \u2227 Via e1 z \u2227 Humans e1 \u2227 Promotes e2 \u2227 Agent e2 x \u2227 Agent e2 e1\"\\n\\n(* Explanation 3: Loss of PALB2 disrupts the localization of BRCA2 to sites of DNA damage, which directly prevents BRCA2 from promoting the joining of undamaged homologous repair molecules in HRR by disrupting its role in the repair process. *)\\naxiomatization where\\n  explanation_3: \"\u2200x y z w e1 e2 e3 e4. LossPALB2 x \u2227 Localization e1 \u2227 BRCA2 y \u2227 SitesDNA z \u2227 Disrupts e2 \u2227 Agent e2 x \u2227 Agent e2 e1 \u2227 To e1 z \u2227 Prevents e3 \u2227 Agent e3 e2 \u2227 Agent e3 y \u2227 Promoting e4 \u2227 Agent e4 y \u2227 Joining e4 \u2227 RepairMolecules w \u2227 InHRR e4 \u2227 DisruptsRole e4\"\\n\\n(* Explanation 4: The disruption of BRCA2 localization due to the loss of PALB2 prevents BRCA2 from performing its role in HRR, specifically in joining undamaged repair molecules, because BRCA2 cannot access the repair sites. *)\\naxiomatization where\\n  explanation_4: \"\u2200x y z w e1 e2 e3. Disruption e1 \u2227 Localization e2 \u2227 BRCA2 x \u2227 LossPALB2 y \u2227 Prevents e3 \u2227 Agent e3 e1 \u2227 Agent e3 x \u2227 PerformingRole e3 \u2227 InHRR e3 \u2227 Joining e3 \u2227 RepairMolecules z \u2227 Access e3 w \u2227 RepairSites w\"\\n\\ntheorem hypothesis:\\n  assumes asm: \"LossPALB2 x \u2227 Action e1 \u2227 BRCA2 y \u2227 RepairMolecules z \u2227 Joining e2 \u2227 Agent e2 y \u2227 Agent e2 z \u2227 InHRR e2\"\\n  (* Hypothesis: Loss of PALB2 prevents the action of BRCA2 in joining undamaged repair molecules in HRR. *)\\n  shows \"\u2200x y z e1 e2. LossPALB2 x \u2227 Action e1 \u2227 BRCA2 y \u2227 RepairMolecules z \u2227 Joining e2 \u2227 Agent e2 y \u2227 Agent e2 z \u2227 InHRR e2 \u27f6 (Prevents e1 e2)\"\\nproof -\\n  (* From the premise, we have the known information about LossPALB2, Action, BRCA2, RepairMolecules, Joining, Agent, and InHRR. *)\\n  from asm have \"LossPALB2 x \u2227 Action e1 \u2227 BRCA2 y \u2227 RepairMolecules z \u2227 Joining e2 \u2227 Agent e2 y \u2227 Agent e2 z \u2227 InHRR e2\" <ATP>\\n  (* Explanation 3 states that Loss of PALB2 disrupts the localization of BRCA2 to sites of DNA damage, which directly prevents BRCA2 from promoting the joining of undamaged homologous repair molecules in HRR. *)\\n  (* This implies that LossPALB2 leads to a disruption that prevents the action of BRCA2 in HRR. *)\\n  (* Therefore, we can conclude that LossPALB2 prevents the action of BRCA2 in joining undamaged repair molecules in HRR. *)\\n  then have \"Prevents e1 e2\" <ATP>\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: patient has a pathogenic mutation in PALB2 (from Explanatory Sentence 1)\\nB: PALB2 encodes a binding partner that localizes BRCA2 to sites of DNA damage (from Explanatory Sentence 1)\\nC: PALB2 links BRCA1 and BRCA2 in HR repair and DNA damage (from Explanatory Sentence 1)\\nD: BRCA2 promotes the joining of undamaged homologous repair molecules via RAD51 homolog 1 in humans (from Explanatory Sentence 2)\\nE: Loss of PALB2 disrupts the localization of BRCA2 to sites of DNA damage (from Explanatory Sentence 3)\\nF: Disruption of BRCA2 localization prevents BRCA2 from promoting the joining of undamaged homologous repair molecules in HRR (from Explanatory Sentence 3)\\nG: BRCA2 cannot access the repair sites (from Explanatory Sentence 4)\\n\\nLogical Relations:\\nImplies(A, B)\\nImplies(patient has a pathogenic mutation in PALB2, PALB2 encodes a binding partner that localizes BRCA2 to sites of DNA damage)\\n--------\\nImplies(A, C)\\nImplies(patient has a pathogenic mutation in PALB2, PALB2 links BRCA1 and BRCA2 in HR repair and DNA damage)\\n--------\\nImplies(B, D)\\nImplies(PALB2 encodes a binding partner that localizes BRCA2 to sites of DNA damage, BRCA2 promotes the joining of undamaged homologous repair molecules via RAD51 homolog 1 in humans)\\n--------\\nImplies(E, Not(B))\\nImplies(Loss of PALB2 disrupts the localization of BRCA2 to sites of DNA damage, Not(PALB2 encodes a binding partner that localizes BRCA2 to sites of DNA damage))\\n--------\\nImplies(E, F)\\nImplies(Loss of PALB2 disrupts the localization of BRCA2 to sites of DNA damage, Disruption of BRCA2 localization prevents BRCA2 from promoting the joining of undamaged homologous repair molecules in HRR)\\n--------\\nImplies(F, Not(D))\\nImplies(Disruption of BRCA2 localization prevents BRCA2 from promoting the joining of undamaged homologous repair molecules in HRR, Not(BRCA2 promotes the joining of undamaged homologous repair molecules via RAD51 homolog 1 in humans))\\n--------\\nImplies(G, Not(D))\\nImplies(BRCA2 cannot access the repair sites, Not(BRCA2 promotes the joining of undamaged homologous repair molecules via RAD51 homolog 1 in humans))\\n--------\\n\\nDerived Implications:\\nImplies(B, Not(F))\\nImplies(PALB2 encodes a binding partner that localizes BRCA2 to sites of DNA damage, Not(Disruption of BRCA2 localization prevents BRCA2 from promoting the joining of undamaged homologous repair molecules in HRR))\\n--------\\nImplies(Not(D), Not(A))\\nImplies(Not(BRCA2 promotes the joining of undamaged homologous repair molecules via RAD51 homolog 1 in humans), Not(patient has a pathogenic mutation in PALB2))\\n--------\\nImplies(F, Not(A))\\nImplies(Disruption of BRCA2 localization prevents BRCA2 from promoting the joining of undamaged homologous repair molecules in HRR, Not(patient has a pathogenic mutation in PALB2))\\n--------\\nImplies(E, Not(D))\\nImplies(Loss of PALB2 disrupts the localization of BRCA2 to sites of DNA damage, Not(BRCA2 promotes the joining of undamaged homologous repair molecules via RAD51 homolog 1 in humans))\\n--------\\nImplies(A, Not(G))\\nImplies(patient has a pathogenic mutation in PALB2, Not(BRCA2 cannot access the repair sites))\\n--------\\nImplies(F, Not(B))\\nImplies(Disruption of BRCA2 localization prevents BRCA2 from promoting the joining of undamaged homologous repair molecules in HRR, Not(PALB2 encodes a binding partner that localizes BRCA2 to sites of DNA damage))\\n--------\\nImplies(G, Not(A))\\nImplies(BRCA2 cannot access the repair sites, Not(patient has a pathogenic mutation in PALB2))\\n--------\\nImplies(D, Not(E))\\nImplies(BRCA2 promotes the joining of undamaged homologous repair molecules via RAD51 homolog 1 in humans, Not(Loss of PALB2 disrupts the localization of BRCA2 to sites of DNA damage))\\n--------\\nImplies(G, Not(B))\\nImplies(BRCA2 cannot access the repair sites, Not(PALB2 encodes a binding partner that localizes BRCA2 to sites of DNA damage))\\n--------\\nImplies(A, Not(F))\\nImplies(patient has a pathogenic mutation in PALB2, Not(Disruption of BRCA2 localization prevents BRCA2 from promoting the joining of undamaged homologous repair molecules in HRR))\\n--------\\nImplies(A, D)\\nImplies(patient has a pathogenic mutation in PALB2, BRCA2 promotes the joining of undamaged homologous repair molecules via RAD51 homolog 1 in humans)\\n--------\\nImplies(B, Not(G))\\nImplies(PALB2 encodes a binding partner that localizes BRCA2 to sites of DNA damage, Not(BRCA2 cannot access the repair sites))\\n--------\\nImplies(A, Not(E))\\nImplies(patient has a pathogenic mutation in PALB2, Not(Loss of PALB2 disrupts the localization of BRCA2 to sites of DNA damage))\\n--------\\nImplies(E, Not(A))\\nImplies(Loss of PALB2 disrupts the localization of BRCA2 to sites of DNA damage, Not(patient has a pathogenic mutation in PALB2))\\n--------\\n'}"
        ]
    }
}